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Abstract
Background
Early accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and
survival. Melanoma and squamous cell carcinoma (SCC) are high risk skin cancers which have the potential to metastasise
and ultimately lead to death, whereas basal cell carcinoma (BCC) is usually localised with potential to infiltrate and damage
surrounding tissue. Anxiety around missing early curable cases needs to be balanced against inappropriate referral and
unnecessary excision of benign lesions. Ultrasound is a non-invasive imaging technique which relies on the measurement of
sound wave reflections from the tissues of the body. At lower frequencies, the deeper structures of the body such as the
internal organs can be visualised, while high frequency ultrasound (HFUS) with transducer frequencies of at least 20MHz,
has a much lower depth of tissue penetration but produces a higher resolution image of tissues and structures closer to the
skin surface. Used in conjunction with clinical or dermoscopic examination of suspected skin cancer, or both, HFUS may
offer additional diagnostic information compared to other technologies.
Objectives
To determine the diagnostic accuracy of HFUS to assist in the diagnosis of (a) melanoma and intraepidermal melanocytic
variants, (b) cutaneous squamous cell carcinoma (cSCC), and (c) basal cell carcinoma (BCC) in adults.
Search methods
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We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central
Register of Controlled Trials; MEDLINE; EMBASE; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of
Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization
International Clinical Trials Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies evaluating HFUS (>= 20 MHz) in adults with lesions suspicious for melanoma, cSCC or BCC, compared with a
reference standard of histological confirmation or clinical follow-up.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form
(based on QUADAS-2). Due to scarcity of data and poor quality of studies, no meta-analysis was undertaken for this review.
For illustrative purposes, estimates of sensitivity and specificity were plotted on coupled forest plots.
Main results
Six studies were included, providing 29 datasets, 20 for diagnosis of melanoma (1125 lesions and 242 melanomas) and 9 for
diagnosis of BCC (993 lesions and 119 BCCs). No data relating to the diagnosis of cSCC were identified.
Studies were generally poorly reported limiting judgements of methodological quality. Half of studies did not set out to
establish test accuracy and all should be considered preliminary evaluations of the potential usefulness of HFUS. There were
particularly high concerns for applicability of findings due to selective study populations and data driven thresholds for test
positivity. Studies reporting qualitative assessments of HFUS images excluded up to 22% of lesions (including some
melanomas) due to them not being visualised by the test.
Derived sensitivities for qualitative HFUS characteristics were at least 83% (95% CI 75% to 90%) for the detection of
melanoma; the combination of three features (lesions appearing hypoechoic, homogenous and well defined) demonstrating
100% sensitivity in two studies, with variable corresponding specificities of 33% (95% CI 20% to 48%) and 73% (95% CI 57%
to 85%) (lower limits of the 95% CIs for sensitivities were 94% and 82% respectively). Quantitative measurement of HFUS
outputs in two studies enabled decision thresholds to be set to achieve 100% sensitivity; specificities were 93% (95% CI 77%
to 99%) and 65% (95% CI 51% to 76%). It was not possible to make summary statements regarding HFUS accuracy for the
diagnosis of BCC due to highly variable sensitivities and specificities.
Authors' conclusions
Insufficient data are available on the potential value of HFUS in the diagnosis of melanoma or BCC. Given the between study
heterogeneity, unclear to low methodological quality and limited volume of evidence, no implications for practice can be
drawn. The main value of the preliminary studies included may be in provision of guidance on the possible components of
future diagnostic rules for diagnosis of melanoma or BCC using HFUS that require future evaluation. A prospective
evaluation of HFUS added to visual inspection and dermoscopy alone in a standard health care setting with a clearly defined
and representative population of participants would be required for a full and proper evaluation of accuracy.
Plain language summary
What is the diagnostic accuracy of high frequency ultrasound for the diagnosis of cutaneous melanoma or
basal cell carcinoma in adults?
Why is improving the diagnosis of skin cancer important?
There are a number of different types of skin cancer. Melanoma is one of the most dangerous forms and it is important that it
is recognised early so that it can be removed. If it is not recognised when first brought to the attention of doctors (also known
as a false negative test result) treatment can be delayed resulting in the melanoma spreading to other organs in the body
and possibly premature death. Cutaneous squamous cell carcinoma and basal cell carcinoma are usually localised skin
cancers, although cutaneous squamous cell carcinoma can spread to other parts of the body and basal cell carcinoma can
cause disfigurement if not recognised early. Diagnosing a skin cancer when it is not really a skin cancer (a false positive
result) may result in unnecessary surgery and other investigations that can cause stress and anxiety to the patient. Making
the correct diagnosis is important. Mistaking one skin cancer for another can lead to the wrong treatment being used or lead
to a delay in effective treatment.
What is the aim of the review?
The aim of this Cochrane review was to find out whether high frequency ultrasound can assist in the diagnosis of skin
cancer. Researchers in Cochrane included six studies to try and answer this question. Five studies were concerned with the
diagnosis of melanoma and three with the diagnosis of basal cell carcinoma.
What was studied in the review?
A number of tools are available to skin cancer specialists which allow a more detailed examination of the skin compared to
examination by the naked eye alone. Currently a dermatoscope is used by most skin cancer specialists, which magnifies the
skin lesion using a natural light. Ultrasound is another non-invasive imaging technique which measures sound wave
reflections from the tissues of the body. High frequency ultrasound can produce a good quality image of structures closer to
the skin surface. When used in addition to a doctor’s examination and dermoscopic examination of skin lesions, high
frequency ultrasound may offer additional useful information to make a more accurate diagnosis.
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What are the main results of the review?
The review included six studies: five studies with a total of 1125 skin lesions suspected of being melanoma and three studies
with a total of 993 lesions suspected of being basal cell carcinoma. No studies concerned with the diagnosis of cutaneous
squamous cell carcinoma were found.
The included studies were small and too different from each other to allow reliable estimates of accuracy to be made for
identifying melanoma or basal cell carcinoma. Half of studies were not actually designed to establish test accuracy and all
our included studies should be considered as preliminary experiments on the potential value of high frequency ultrasound.
The main value of the studies included may be in helping future researchers understand the best ways of interpreting high
frequency ultrasound for the diagnosis of melanoma or basal cell carcinomaCC that will require future evaluation.
How reliable are the results of the studies of this review?
Study results are not very reliable when considered in total. The small number and variability between studies included in this
review reduces the reliability of findings. Included studies also had important limitations. In particular, those taking part in the
studies and the way in which the tests were used may not reflect real life situations.
Who do the results of this review apply to?
Studies were all conducted in Europe. Average age was reported in only one study (55.3 years). The percentage of people
with a final diagnosis of melanoma ranged between 14% and 58% and ranged from 8% to 49% for basal cell carcinoma. It
was not possible to tell whether suspicion of skin cancer in study participants was based on clinical examination alone, or
both clinical and dermoscopic examination.
What are the implications of this review?
At present, there is simply not enough good research on the use of high frequency ultrasound to help diagnose skin cancers
to say very much. The results of this review suggest that high frequency ultrasound has potential to separate melanoma or
basal cell carcinoma from particular types of benign lesions, but it is not yet clear whether it can adequately distinguish these
skin cancers from the full range of the sorts of things that patients show to their doctors in everyday practice. More studies
looking at the use of high frequency ultrasound alongside dermoscopy or other microscopic techniques (such as reflectance
confocal microscopy) in well described groups of people with suspicious skin lesions are needed.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies, biopsy, clinical follow up, or specialist clinician diagnosis were the reference standards.
Background 
This review is one of a series of Cochrane Diagnostic Test Accuracy (DTA) reviews on the diagnosis and staging of
melanoma and keratinocyte skin cancers conducted for the National Institute for Health Research (NIHR) Cochrane
Systematic Reviews Programme. Appendix 1 shows the content and structure of the programme. Appendix 2 provides a
glossary of terms used, and a table of acronyms used is provided in Appendix 3.
Target condition being diagnosed
There are three main forms of skin cancer. Melanoma has the highest skin cancer mortality (Cancer Research UK 2017
); however, the most common skin cancers in Caucasian populations are those arising from keratinocyte cells: basal
cell carcinoma and cutaneous squamous cell carcinoma (Gordon 2013; Madan 2010). In 2003, the World Health
Organization estimated that between two and three million ‘non-melanoma’ skin cancers (of which BCC and cSCC are
estimated to account for around 80% and 16% of cases respectively) and 132,000 melanoma skin cancers occur
globally each year (WHO 2003).
In this diagnostic test accuracy review there are three target conditions of interest (a) melanoma, (b) basal cell carcinoma
(BCC), (c) cutaneous squamous cell carcinoma (cSCC).
Melanoma
Melanoma arises from uncontrolled proliferation of melanocytes - the epidermal cells that produce pigment or melanin.
Cutaneous melanoma refers to any skin lesion with malignant melanocytes present in the dermis, and includes superficial
spreading, nodular, acral lentiginous, and lentigo maligna melanoma variants (see Figure 1). Melanoma in situ refers to
malignant melanocytes that are contained within the epidermis and have not yet invaded the dermis, but are at risk of
progression to melanoma if left untreated. Lentigo maligna, a subtype of melanoma in situ in chronically sun-damaged skin,
denotes another form of proliferation of abnormal melanocytes. Melanoma in situ and lentigo maligna are both atypical
intraepidermal melanocytic variants. All forms of melanoma in situ can progress to invasive melanoma if its growth breaches
the dermo-epidermal junction during a vertical growth phase, although malignant transformation is both lower and slower for
lentigo maligna than for melanoma in situ (Kasprzak 2015). Melanoma is one of the most dangerous forms of skin
cancer, with the potential to metastasise to other parts of the body via the lymphatic system and blood stream. It
accounts for only a small percentage of skin cancer cases but is responsible for up to 75% of skin cancer deaths (Boring
1994; Cancer Research UK 2017).
The incidence of melanoma rose to over 200,000 newly diagnosed cases worldwide in 2012 (Erdmann 2013; Ferlay 2015
), with an estimated 55,000 deaths (Ferlay 2015). The highest incidence is observed in Australia with 11,405 new cases
of melanoma of the skin (ACIM 2014) and in New Zealand with 2,341 registered cases (HPA and MelNet NZ 2014) in
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2010. For 2014 in the USA, the predicted incidence was 73,870 per annum and the predicted number of deaths 9,940
(Siegel 2015). The highest rates in Europe are seen in north-western Europe and the Scandinavian countries, with
highest incidence reported in Switzerland of 25.8 per 100,000 in 2012. Rates in the UK have trebled from 4.6 and 6.0
per 100,000 in men and women, respectively in England in 1990, to 18.6 and 19.6 per 100,000 in 2012 (EUCAN 2012
). In the UK, melanoma has one of the fastest rising incidence rates of any cancer, and has had the biggest projected
increase in incidence between 2007 and 2030 (Mistry 2011). In the decade leading up to 2013, age standardised
incidence increased by 46%, with 14,500 new cases in 2013 and 2459 deaths in 2014 (Cancer Research UK 2017).
Rates are higher in women than in men; however, the rate of incidence in men is increasing faster than in women (
Arnold 2014).The rising incidence in melanoma is thought to be primarily related to an increase in recreational sun
exposure and tanning bed use and an increasingly ageing population with higher lifetime recreational ultraviolet (UV)
exposure, in conjunction with possible earlier detection (Linos 2009; Belbasis 2016). Putative risk factors, including eye and
hair colour, skin type and density of freckles, history of melanoma, sunburn, and presence of particular lesion types, are
reviewed in detail in Belbasis 2016.
A database of over 40,000 US patients from 1998 onwards which assisted the development of the 8th American
Joint Committee on Cancer (AJCC) Staging System indicated a five-year survival of 97% to 99% for stage I
melanoma, dropping to between 32% and 93% in stage III disease depending on tumour thickness, the
presence of ulceration and number of involved nodes (Gershenwald 2017). While these are substantial increases relative
to survival in 1975 (Cho 2014), increasing incidence between 1975 and 2010 means that mortality rates have reportedly
remained static. This observation coupled with increasing incidence of localised disease, suggests that improvements in
survival may be due to earlier detection and heightened vigilance (Cho 2014). Targeted therapies for stage IV
melanoma have improved survival expectation and immunotherapies are evolving such that long term survival is
being documented (e.g. using BRAF-inhibitors (Chapman 2012; Villanueva 2010) and MEK inhibitors (Larkin 2014; 
Dummer 2014), and immunomodulation (Chapman 2011; Hamid 2013; Hodi 2010)).
Basal cell carcinoma
BCC can arise from multiple stem cell populations, including from the follicular bulge and interfollicular
epidermis (Grachtchouk 2011). BCC growth is usually localised, but it can infiltrate and damage surrounding tissue,
sometimes causing considerable destruction and disfigurement, particularly when located on the face (Figure 1).
The four main subtypes of BCC are superficial, nodular, morphoeic or infiltrative and pigmented. BCCs typically
present as slow-growing, asymptomatic papules, plaques, or nodules which may subsequently bleed or form ulcers
that do not heal (Firnhaber 2012). People with a BCC often present themselves to healthcare professionals with a
non-healing lesion rather than specific symptoms such as pain. Many lesions are diagnosed incidentally (Gordon 2013).
BCC most commonly occurs on sun-exposed sites on the head and neck (McCormack 1997) and are more common in
men and in people over the age of 40. A rising incidence of BCC in younger people has been attributed to increased
recreational sun exposure (Bath-Hextall 2007; Gordon 2013; Musah 2013). Other risk factors include Fitzpatrick
skin phototypes I and II (Fitzpatrick 1975; Lear 1997; Maia 1995), previous skin cancer history, immunosuppression,
arsenic exposure, and genetic predisposition such as in basal cell naevus (Gorlin) syndrome (Gorlin 2004; Zak-Prelich
2004). Annual incidence is increasing worldwide; Europe has experienced an average increase of 5.5% per year over
the last four decades, the USA 2% per year, while estimates for the UK show incidence appears to be increasing more
steeply at a rate of an additional 6 / 100,000 persons per year (Lomas 2012). The rising incidence has been
explained by an ageing population, changes in the distribution of known risk factors, particularly ultraviolet
radiation, and improved detection due to the increased awareness amongst both practitioners and the general
population (Verkouteren 2017). Hoorens 2016 points to evidence for a gradual increase in the size of BCCs over time, with
delays in diagnosis ranging from 19 to 25 months.
According to National Institute for Health and Care Excellence (NICE) guidance (NICE 2010), low risk BCCs are
nodular lesions occurring in patients older than 24 years old who are not immunosuppressed and do not have Gorlin
syndrome. Furthermore, they should be located below the clavicle, should be small (< 1 cm) with well-defined margins,
not recurrent following incomplete excision and not in awkward or highly visible locations (NICE 2010). Superficial
BCCs are also typically low risk and may be amenable to medical treatments such as photodynamic therapy or
topical chemotherapy (Kelleners-Smeets 2017). Assigning BCCs as low or high risk influences the management
options (Batra 2002; Randle 1996).
Advanced locally destructive or aggressive BCC can be found on “high risk” anatomical areas such as the eyebrow,
eyelid, nose, ear and temple (these are at higher risk of invisible spread and therefore are more at risk of being
incompletely excised (Baxter 2012)) (Lear 2014) and can arise from long-standing untreated lesions or from a
recurrence of aggressive basal cell carcinoma after primary treatment (Lear 2012). Very rarely, BCC metastasises
to regional and distant sites resulting in death, especially cases of large neglected lesions in those who are
immunosuppressed or those with Gorlin syndrome (McCusker 2014). Rates of metastasis are reported at 0.0028% to
0.55% (Lo 1991), with very poor survival rates. It is recognised that basosquamous carcinoma (more like a high risk
SCC in behaviour and not considered a true BCC) is likely to have accounted for many cases of apparent metastases
of BCC hence the spuriously high reported incidence in some studies of up to 0.55%, which is not seen in clinical
practice (Garcia 2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinising cells of the epidermis or its appendages. People with cSCC often present
with an ulcer or firm (indurated) papule, plaque, or nodule (Griffin 2016) often with an adherent crust and poorly
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defined margins (Madan 2010). cSCC can arise in the absence of a precursor lesion or it can develop from pre-existing
actinic keratosis or Bowen's disease (considered by some to be cSCC in situ); the estimated annual risk of progression
being <1% to 20% for newly arising lesions (Alam 2001) and 5% for pre-existing lesions (Kao 1986). It remains
locally invasive for a variable length of time, but has the potential to spread to the regional lymph nodes or via the
bloodstream to distant sites, especially in immunosuppressed individuals (Lansbury 2010). High risk lesions are those
arising on the lip or ear, recurrent cSCC, lesions arising on non-exposed sites, scars or chronic ulcers, tumours more
than 20mm in diameter, depth of invasion greater than 4mm and poor differentiation on pathological examination (Motley
2009). Perineural nerve invasion of at least > 0.1 mm in diameter is a further documented risk factor for high risk cSCC
(Carter 2013).
Chronic ultraviolet light exposure through recreation or occupation is strongly linked to cSCC occurrence (Alam 2001). It
is particularly common in people with fair skin and in less common genetic disorders of pigmentation, such as albinism,
xeroderma pigmentosum, and recessive dystrophic epidermolysis bullosa (RDEB) (Alam 2001). Other recognised
risk factors include immunosuppression; chronic wounds; arsenic or radiation exposure; certain drug treatments,
such as voriconazole and BRAF mutation inhibitors; and previous skin cancer history (Baldursson 1993; Chowdri 1996; 
Dabski 1986; Fasching 1989; Lister 1997; Maloney 1996; O'Gorman 2014). In solid organ transplant recipients,
cSCC is the most common form of skin cancer; the risk of developing cSCC has been estimated at 65 to 253 times
that of the general population (Hartevelt 1990; Jensen 1999; Lansbury 2010). Overall, local and metastatic
recurrence of cSCC at five years is estimated at 8% and 5% respectively. The five-year survival rate of
metastatic cSCC of the head and neck is around 60% (Moeckelmann 2018).
Treatment
For primary melanoma, the mainstay of definitive treatment is wide local surgical excision of the lesion, to remove
both the tumour and any malignant cells that might have spread into the surrounding skin (Sladden 2009; Marsden 2010; 
NICE 2015a; Garbe 2016; SIGN 2017). Recommended lateral surgical margins vary according to tumour thickness (Garbe
2016) and stage of disease at presentation (NICE 2015a).
Treatment options for BCC and cSCC include surgery, other destructive techniques such as cryotherapy or
electrodessication and topical chemotherapy. A Cochrane systematic review of 27 randomised controlled trials (RCTs)
of interventions for BCC found very little good quality evidence for any of the interventions used (Bath-Hextall 2007a).
Complete surgical excision of primary BCC has a reported five-year recurrence rate of < 2% (Griffiths 2005; Walker 2006
), leading to significantly fewer recurrences than treatment with radiotherapy (Bath-Hextall 2007a). After apparent
clear histopathological margins (serial vertical sections) after standard excision biopsy with 4mm surgical peripheral
margins taken there is a 5-year reported recurrence rate of around 4% (Drucker 2017). Mohs micrographic surgery,
whereby horizontal sections of the tumour are microscopically examined intraoperatively, and re-excision is undertaken
until the margins are tumour-free, can be considered for high risk lesions on the face where standard wider excision
margins might lead to incomplete excision or considerable functional impairment (Bath-Hextall 2007a; Motley 2009; 
Lansbury 2010; Stratigos 2015). Bath-Hextall and colleagues (Bath-Hextall 2007a) found a single trial comparing
Mohs micrographic surgery with a 3mm surgical margin excision in BCC (Smeets 2004); the update of this study showed
non-significantly lower recurrence at 10 years with Mohs micrographic surgery (4.4% compared to 12.2% after surgical
excision, P = 0.10) (van Loo 2014).
The main treatments for high risk BCC are standard surgical excision, Mohs micrographic surgery or radiotherapy.
For low risk or superficial subtypes of BCC, or for small and or multiple BCCs at low risk sites (Marsden 2010),
destructive techniques other than excisional surgery may be used (e.g. electrodessication and curettage or cryotherapy
(Alam 2001; Bath-Hextall 2007a)). Alternatively non-surgical (or non-destructive) treatments may be considered (Bath-
Hextall 2007a; Kim 2014; Drew 2017), including topical chemotherapy imiquimod (Williams 2017), 5-fluorouracil (5-FU) (
Arits 2013), ingenol mebutate (Nart 2015) and photodynamic therapy (PDT) (Roozeboom 2016). Non-surgical
treatments are most frequently used for superficial forms of BCC, with one head to head trial suggesting topical
imiquimod is superior to PDT and 5-FU (Jansen 2018). Although non-surgical techniques are increasingly used, they do
not allow histological confirmation of tumour clearance, and their use is dependent on accurate characterisation of the
histological subtype and depth of tumour. The 2007 systematic review of BCC interventions found limited evidence from
very small RCTs for these approaches (Bath-Hextall 2007a), which have only partially been addressed by subsequent
studies (Bath-Hextall 2014; Kim 2014; Roozeboom 2012). Most BCC trials have compared interventions within the same
treatment class, and few have compared medical versus surgical treatments (Kim 2014).
Vismodegib, a first-in-class Hedgehog signalling pathway inhibitor is now available for the treatment of metastatic or
locally advanced BCC based on the pivotal study ERIVANCE BCC (Sekulic 2012). It is licensed for use in these
patients where surgery or radiotherapy is inappropriate, e.g. for treating locally advanced periocular and orbital BCCs
with orbital salvage of patients who otherwise would have required exenteration (Wong 2017). However, NICE has
recently recommended against the use of vismodegib based on cost effectiveness and uncertainty of evidence (NICE 2017).
A systematic review of interventions for primary cSCC found only one RCT eligible for inclusion (Lansbury 2010). Current
practice therefore relies on evidence from observational studies, as reviewed in Lansbury 2013, for example. Surgical
excision with predetermined margins is usually the first-line treatment (Motley 2009; Stratigos 2015). Estimates of
recurrence after Mohs micrographic surgery, surgical excision, or radiotherapy, which are likely to have been
evaluated in higher risk populations, have shown pooled recurrence rates of 3%, 5.4% and 6.4%, respectively with
overlapping confidence intervals; the review authors advise caution when comparing results across treatments (Lansbury
2013).
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Index test(s)
Ultrasound is a non-invasive imaging technique which essentially relies on the measurement of sound wave reflections
from the tissues of the body. A transducer generates a focused beam of sound pulses and measures the reflections
(or echoes) produced by structures within the tissue. The spatial location of a tissue structure that produced an echo is
determined in the lateral direction (parallel to the skin surface) by the position of the sound beam (known) and in the
axial (depth) direction by the return time of the echo (measured) and the speed of sound in the tissue (known to a
good approximation) (Figure 2) (Barcaui 2016; Kleinerman 2012). An important parameter is the range of
acoustic frequencies used to form the image. While low frequency ultrasound visualises the deeper structures of
the body, such as the internal organs, high frequency ultrasound (HFUS), defined here as having centre (or
median) frequency of at least 20MHz, has a much lower depth of tissue penetration but produces a higher
resolution image of tissues and structures closer to the skin surface (Kleinerman 2012). Frequencies of 20 to 25
MHz allow visualisation of both the dermis and epidermis while higher frequencies of 50 MHz and above visualise
the epidermis only (Kleinerman 2012). An example of a currently commercially available HFUS scanner is provided in Figure
3; the cost of the system can range from EUR 5,500 for a Windows tablet-based non-real-time system that works at 20
MHz (not shown), to around EUR 27,000 for a laptop-based system (Figure 3) which provides real-time images and
works up to a frequency of 50 MHz (as well as 20 MHz) (Cortex Technology 2018).
In B-mode (brightness mode) ultrasound echography, the image brightness is modulated according to the amplitude
of the echoes (echogenicity). This in turn is determined by a) the values of sound speed and mass-density within an
echo-producing structure relative to those values in the surrounding medium, and b) the size, shape, orientation, and
number-density of such structures (Barcaui 2016). Please see the following examples.
Structural proteins, such as collagen and keratin, are dense and have high sound speed and generate strong echoes
(termed hyperechoic or echogenic) when the fibres are thick, densely packed, and oriented mostly perpendicular to the
ultrasound beam (e.g. reticular dermis).
Adipose tissue; highly cellular lesions with little collagen or keratin; and regions where the collagen bundle size is small
(some lesions) or oriented mostly parallel to the sound beam (e.g. papillary dermis), or both, generate weak echoes
(termed hypoechoic or echo poor).
Liquids (e.g. as in simple cysts) generate no echoes and are referred to as anechoic (Bamber 1992; Harland 1993).
The use of HFUS has been investigated for diagnosing a range of skin conditions, including skin cancer,
infection, and inflammatory conditions (Kleinerman 2012), with malignant lesions reportedly appearing as hypoechogenic
areas surrounded by a hyperechogenic dermis. Melanomas in particular also reportedly appear homogenous and with well-
defined margins (e.g. Harland 2000). Evaluations have also been made of the ability of HFUS to quantitatively
differentiate melanomas from other lesion types using entry echogenicity and attenuation (the latter being the rate of
reduction in echo signal with depth). These features have been reported to be particularly useful for distinguishing
melanoma from seborrhoeic keratosis, for example (Harland 2000; Rallan 2007; see Figure 4), and as being measurable
even when a given lesion cannot be visualised on ultrasound.
Clinical Pathway 
The diagnosis of melanoma can take place in primary, secondary, and tertiary care settings by both generalist and
specialist healthcare providers. In the UK, people with concerns about a new or changing lesion will usually present
first to their general practitioner or, less commonly, directly to a specialist in secondary care, which could include a
dermatologist, plastic surgeon, or other specialist surgeon (such as an ear, nose, and throat (ENT) specialist or
maxillofacial surgeon), or ophthalmologist (Figure 5). Current UK guidelines recommend that all suspicious
pigmented lesions presenting in primary care should be assessed by taking a clinical history and visual inspection
using the revised seven-point checklist (MacKie 1990). Those with suspected melanoma or cSCC should be referred
for appropriate specialist assessment within two weeks (Chao 2013; London Cancer Alliance 2013; Marsden 2010; NICE
2015a). Evidence is emerging, however, to suggest that excision of melanoma by GPs is not associated with
increased risk compared with outcomes in secondary care (Murchie 2017). In the UK, low risk BCC are usually
recommended for routine referral, with urgent referral for those in whom a delay could have a significant impact on
clinical outcomes, for example due to large lesion size or critical site (NICE 2015b). Appropriately qualified generalist
care providers increasingly undertake management of low risk BCC in the UK such as by excision of low risk lesions (NICE
2010). Similar guidance is in place in Australia (CCAAC Network 2008).
For referred lesions, the specialist clinician will also use history-taking, inspection of the lesion (in comparison with
other lesions on the skin), usually in conjunction with dermoscopic examination, and palpation of the lesion and
associated regional nodal basins to inform a clinical decision. If melanoma is suspected, then urgent 2mm excision
biopsy is recommended (Lederman 1985; Lees 1991); for cSCC predetermined surgical margin excision or a diagnostic
biopsy may be considered. BCC and pre-malignant lesions potentially eligible for nonsurgical treatment may undergo a
diagnostic biopsy before initiation of therapy. Equivocal melanocytic lesions for which a definitive clinical diagnosis cannot be
reached may undergo surveillance to identify any lesion changes that would indicate excisional biopsy or reassurance and
discharge for those that remain stable over a period of time.
Prior test(s)
The diagnosis of skin cancer is based on history-taking and clinical examination. In the UK, this is typically
undertaken at two decision points – first in the GP surgery where a decision is made to refer or not to refer, and then
a second time by a dermatologist or other secondary care clinician where a decision is made to biopsy or excise or
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not. Visual inspection of the skin is undertaken iteratively, using both implicit pattern recognition (non-analytical
reasoning) and more explicit ‘rules’ based on conscious analytical reasoning (Norman 2009), the balance of which
will vary according to experience and familiarity with the diagnostic question. Various attempts have been made to
formalise the “mental rules” involved in analytical pattern recognition for melanoma (Friedman 1985; Grob 1998; MacKie
1985; MacKie 1990; Sober 1979; Thomas 1998) however visual inspection for keratinocyte skin cancers relies
primarily on pattern recognition. Accuracy has been shown to vary according to the expertise of the clinician. Primary
care physicians have been found to miss over half of BCC (Offidani 2002) and to inappropriately diagnose one third
of BCC (Gerbert 2000). In contrast, an Australian study found that trained dermatologists were able to detect 98% of
BCC, but with a specificity of only 45% (Green 1988).
A range of technologies have emerged to aid diagnosis to reduce the number of diagnostic biopsies or
inappropriate surgical procedures. Dermoscopy using a hand-held microscope has become the most widely used
tool for clinicians to improve diagnostic accuracy of pigmented lesions, in particular for melanoma (Argenziano 1998; 
Argenziano 2012; Haenssle 2010; Kittler 2002), although is less well established for the diagnosis of BCC or cSCC.
The diagnostic accuracy, and comparative accuracy, of visual inspection and dermoscopy have been evaluated in a
further three reviews in this series (Dinnes 2018a; Dinnes 2018b, Dinnes 2018c).
Role of index test(s)
Used in conjunction with clinical or dermoscopic suspicion of malignancy, or both, in pigmented lesions, HFUS may have a
potential role in patient management as an additional test to identify those lesions requiring excision. The status of current
medical practice and patient benefit for melanoma is particularly suited to improvement by any cost-effective diagnostic
imaging method that might be developed, since early diagnosis that leads to complete excision of primary melanoma before
metastatic spread has occurred, almost always results in a cure. The probability of metastases increases dramatically with
increasing depth of tumour invasion of the primary melanoma (known as the Breslow thickness). This is assessed by
histological examination after excision but has the potential to be assessed by imaging in vivo. One of the postulated
advantages of HFUS is its ability to rule out melanoma as a potential differential diagnosis, by identifying pigmented
seborrhoeic keratosis (a benign skin lesion) for example.
Although the primary aim in diagnosing potentially life-threatening conditions such as melanoma is to minimise false negative
diagnoses (to avoid delay to diagnosis and even death), a test that can reduce false positive clinical diagnoses without
missing true cases of disease has clear patient and resource benefits. False-positive diagnoses not only cause unnecessary
scarring from a biopsy or excision procedure, but also increase patient anxiety whilst they await the definitive histological
results and increase healthcare costs as the number needed to remove to yield one melanoma diagnosis increases.
Pigmented lesions are common so the resource implication for even a small increase in the threshold to excise lesions in
populations where melanoma rates are increasing, will avoid a considerable healthcare burden to both patient and
healthcare provider, as long as lesions that are not excised turn out to be harmless.
Delay in diagnosis of a BCC as a result of a false-negative test is not as serious as for melanoma because BCCs are usually
slow-growing and very unlikely to metastasise. However, delayed diagnosis can result in larger and more complex surgical
procedures with consequent greater morbidity. Very sensitive diagnostic tests for BCC however may compromise on lower
specificity leading to a higher false-positive rate, and an enormous burden of skin surgery, such that a balance between
sensitivity and specificity is needed. As with melanoma, the consequences of falsely reassuring a person with cSCC that they
do not have skin cancer can be serious and potentially fatal. Thus, a good diagnostic test for cSCC should demonstrate high
sensitivity and a corresponding high negative predictive value. A test that can reduce false positive clinical diagnoses without
missing true cases of disease has patient and resource benefits. False-positive clinical diagnoses not only cause
unnecessary morbidity from the biopsy, but could lead to initiation of inappropriate therapies and also increase patient
anxiety.
HFUS has also been evaluated as a method for non-invasive measurement of melanoma thickness in vivo (Jasaitiene 2011; 
Machet 2009; Meyer 2014) to allow for a single surgical procedure to excise melanomas with the appropriate margin
and, in addition to its optical B-mode imaging cousin, optical coherence tomography (Wang 2013), for appropriate
treatment planning for BCC (Crisan 2013). For example, there is potential for refining surgical procedures, as well as the
increased use and efficacy of non-surgical methods of treating BCC, if non-invasive imaging can be developed which allows
confirmation of tumour clearance. None of these uses are under consideration in this review.
Alternative test(s)
Doppler ultrasound, unlike B-mode ultrasound, measures moving structures such as blood cells, as opposed to
stationary tissues (Kleinerman 2012), and shows relative speed of blood flow as well as relative vessel size and
density. In skin cancer, it can be used in combination with B-mode HFUS and may have value for staging or
assessing the aggressiveness of malignancy due to increased vascular proliferation. Doppler ultrasound may be
useful in preoperative staging due to correlation between extent of vascularisation and blood flow with Breslow
thickness. As a stand-alone technique, Doppler ultrasound is not useful to differentiate skin cancers from benign
lesions (Kleinerman 2012) and is therefore not included as an index test, however its use in combination with high frequency
ultrasound has been considered as a means of improving lesion discrimination.
A number of other tests which may have a role for the diagnosis of skin cancer have been reviewed as part of our
series of Cochrane DTA reviews on the diagnosis of skin cancer, for example, visual inspection and dermoscopy (Dinnes
2018a; Dinnes 2018b; Dinnes 2018c) reflectance confocal microscopy (RCM) (Dinnes 2018d; Dinnes 2018e),
optical coherence tomography (OCT) (Ferrante di Ruffano 2018a), and computer-aided diagnosis (CAD) techniques
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applied to various types of images including those generated by dermoscopy, diffuse reflectance spectrophotometry
(DRS) and electrical impedance spectroscopy (EIS) (Ferrante di Ruffano 2018b).
RCM and OCT are two alternative ways to achieve depth-resolved optical reflectance imaging. To attain axial
resolution, RCM uses a very low numerical aperture with out-of-focus data suppression while OCT uses
interferometry to isolate optical reflections at a defined echo time (conceptually similar to HFUS). They are emerging
as noninvasive adjuncts to dermoscopy in a specialist setting, and RCM potentially as an alternative to dermoscopy
for skin cancer diagnosis (Edwards 2016).
RCM and OCT differ from each other in that RCM tends to use a shorter wavelength (830nm as opposed to 1305nm
for OCT), has considerably less penetration (RCM < 300 µm; OCT < 2 mm), poorer depth of focus (RCM 3-5 µm;
OCT 1 mm) and more limited basic field of view (RCM basic 500 x 500 µm in the horizontal plane; OCT basic 6 x 6
mm) than OCT, but has better lateral resolution (RCM 1 µm, cellular; OCT 7.5 µm, near cellular). They have similar
axial resolution however (RCM 3-5 µm; OCT 5 µm), and both have fields of view that are extendible by mechanical
scanning and image mosaicking, although for equivalent fields of view 3D imaging is much faster with OCT (RCM for
mosaicked field of view and stack > 10 min; OCT 6 cross-sectional frames per second, < 2 min for 6 x 6 x 2mm
volume). With RCM, the contrast for the monochrome images produced is achieved by the variation of the optical
scattering properties within the skin when illuminated by a near-infrared light. At a wavelength of 830nm the greatest
contrast is achieved from melanin, so that RCM is advocated as being particularly useful for assessing pigmented
lesions (Dinnes 2018d). Similar to Doppler ultrasound but with higher resolution, vascular flow information can be
extracted from OCT images, allowing neovascularisation to be visualised, which has potential for earlier diagnosis
of melanoma (Themstrup 2015; Kokolakis 2012).
CAD or artificial intelligence-based techniques use predefined algorithms to process and manipulate acquired data to
identify the features that discriminate malignant from benign lesions. The use of CAD-based techniques has potential
for both reducing the subjectivity of, and de-skilling, the diagnosis of skin lesions. Although such techniques have
most commonly been applied to digital dermoscopy images (Rajpara 2009; Esteva 2017) they may be applied to several
types of images or spectra (e.g. Wallace 2000).
For example, SIAscopy™ and MelaFind® are based on diffuse reflectance spectrophotometry. DRS also uses optical
reflectance, albeit not depth-resolved, but distinguishes between lesion types based on the lesion-average spectral shape
and calibrated level of reflected light for wavelengths continuously varying from the ultraviolet (320 nm) to the near infrared
(1100 nm) with a high spectral resolution (4 nm) (e.g. Marchesini 1992; Wallace 2000a). The extension to imaging
spectrophotometry (DRSi) to allow spatial (dermoscopic) as well as spectral information to contribute to the
diagnosis (Haddock 2003) has resulted in the development of handheld DRSi units (Bish 2014). SIAscopy™ (Moncrieff 2002;
Walter 2012) and MelaFind® (Monheit 2011; Wells 2012; Hauschild 2014) are two such units with limited spectral
capability which have been evaluated in both primary and secondary care settings. DRSi may also be combined with
HFUS (Bamber 2007). Such approaches remain under development.
The Nevisense™ system is based on electrical impedance spectroscopy (EIS). EIS measures a combination of
resistance and capacitance of the tissue as a function of frequency of an alternating applied voltage. At high
frequencies, conduction occurs easily through all tissue components, including cells, but at low frequencies current
tends to flow only through the extracellular space. The spectral shape is thus sensitive to cellular components and
dimensions, internal structure and cellular arrangements. The Nevisense™ EIS system measures at multiple depths
and at 35 frequencies logarithmically distributed from 1.0 kHz to 2.5 MHz using a 5 x 5 mm area electrode covered
in tiny pins that penetrate into the stratum corneum. It has been evaluated and found to have high sensitivity but low
specificity for melanoma (Malvehy 2014; Braun 2017), with concern over possible increase in needless excision of
benign atypical melanocytic lesions (Ceder 2016) despite an indication of promise for reducing the need for short-term
sequential digital dermoscopy (Rocha 2017).
DRS and EIS have not been the subject of individual test reviews due to an anticipated lack of data, however where
available, CAD-based uses of these techniques have been included in our review of CAD for the detection of skin
cancer (Ferrante di Ruffano 2018b).
Evidence permitting, the accuracy of available tests will be compared in an overview review, exploiting within-study
comparisons of tests and allowing the analysis and comparison of commonly used diagnostic strategies where tests may be
used singly or in combination.
Rationale
Our series of reviews of diagnostic tests used to assist clinical diagnosis of skin cancer aims to identify the most accurate
approaches to diagnosis and provide clinical and policy decision-makers with the highest possible standard of evidence
on which to base decisions. With increasing melanoma and basal cell carcinoma incidence and the push towards the use
of dermoscopy and other high resolution image analysis in primary care, the anxiety around missing early malignant
lesions needs to be balanced against the risk of too many referrals, to avoid sending too many people with benign
lesions for a specialist opinion. It is questionable whether all skin cancers picked up by sophisticated techniques, even in
specialist settings, help to reduce morbidity and mortality, and it is a concern that newer technologies run the risk of
increasing false-positive diagnoses. It is also possible that use of some technologies, e.g. widespread use of dermoscopy
in primary care with little or no training, could actually result in harm by missing melanomas if they are used as
replacement technologies for traditional history-taking and clinical examination of the entire skin. Many branches of
medicine have noted the danger of such "gizmo idolatry" amongst doctors (Leff 2008).
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To date, the use of tests such as RCM has been limited by expense (in terms of both equipment and staff time) and the need
for specialised training. If shown to be sufficiently accurate, a test such as HFUS could prove to be a relatively low cost tool
to assist in the earlier diagnosis and better management of skin cancer.
This review follows a generic protocol which covers the full series of Cochrane DTA reviews for the diagnosis of
melanoma (Dinnes 2015a) and keratinocyte skin cancers (Dinnes 2015b). The Background and Methods sections of
this review therefore use some text that was originally published in the protocols (Dinnes 2015a; Dinnes 2015b) and
text that overlaps some of our other reviews (Dinnes 2018a; Dinnes 2018b; Dinnes 2018c).
Objectives 
To determine the diagnostic accuracy of high frequency ultrasound to assist in the diagnosis of cutaneous invasive1.
melanoma and atypical intraepidermal melanocytic variants in adults.
To determine the diagnostic accuracy of high frequency ultrasound to assist in the diagnosis of basal cell carcinoma in2.
adults.
To determine the diagnostic accuracy of high frequency ultrasound to assist in the diagnosis of cutaneous squamous cell3.
carcinoma in adults.
Secondary objectives
To determine the diagnostic accuracy of Doppler ultrasound in combination with high frequency ultrasound for the
diagnosis of each of the three target conditions (cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants, BCC or cSCC). We set out to address a range of potential sources of heterogeneity for
investigation across our series of reviews, as outlined in our generic protocols (Dinnes 2015a; Dinnes 2015b) and described
in Appendix 4; however our ability to investigate these was necessarily limited by the available data on each individual test
reviewed. Ultimately no heterogeneity investigations were conducted for this review of HFUS.
Methods 
Criteria for considering studies for this review
Types of studies 
We included test accuracy studies that allow comparison of the result of the index test with that of a reference standard,
including the following:
studies where all participants receive a single index test and a reference standard;
studies where all participants receive more than one index test(s) and reference standard;
studies where participants are allocated (by any method) to receive different index tests or combinations of index tests
and all receive a reference standard (between-person comparative studies (BPC));
studies that recruit series of participants unselected by true disease status (referred to as case series for the purposes of
this review);
diagnostic case-control studies that separately recruit diseased and non-diseased groups (see Rutjes 2005);
both prospective and retrospective studies; and
studies where previously acquired clinical or dermoscopic images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2x2 contingency data or if they included less than five melanoma, BCC
or cSCC cases or less than five benign lesions.
Participants
We included studies in adults with lesions suspicious for skin cancer. We excluded studies that recruited only
participants with malignant diagnoses and studies that compared test results in participants with malignancy compared
with test results based on 'normal' skin as controls, due to the bias inherent in such comparisons (Rutjes 2006). We excluded
studies conducted in children, or which clearly reported inclusion of more than 50% of participants aged 16 and under.
Index tests
Studies evaluating HFUS alone or in combination with Doppler ultrasound were eligible. HFUS was considered to have been
evaluated if the centre (or median) frequency of the transmitted pulse was at least 20MHz.
Studies should ideally evaluate a predefined 'rule' or algorithm describing combinations of ultrasound characteristics that
determine the presence or absence of melanoma, BCC or cSCC. However, as HFUS is in a relatively early phase of
development, studies were included if 2x2 contingency table data could be extracted based on the presence or absence of at
least two ultrasound features related to tissue morphology or acoustic properties, for example echogenicity, homogeneity of
appearance and definition of margins. Studies attempting to quantify HFUS parameters were also eligible for inclusion. There
was no requirement for studies to have explicitly set out to estimate the diagnostic accuracy of the parameters assessed.
No exclusions were made according to test observer experience or qualifications.
Target conditions
The target conditions were defined as the detection of:
any form of invasive cutaneous melanoma or atypical intraepidermal melanocytic variants (i.e. including melanoma in situ,
or lentigo maligna)
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BCC (all subtypes)
cSCC.
Reference standards
The ideal reference standard was histopathological diagnosis of the excised lesion or biopsy sample in all eligible lesions. A
qualified pathologist or dermatopathologist should perform histopathology. Ideally, reporting should be standardised detailing
a minimum dataset to include the histopathological features of melanoma to determine the American Joint Committee on
Cancer (AJCC) Staging System (e.g. Slater 2014). We did not apply the reporting standard as a necessary inclusion
criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of those undergoing the index test) was of concern given that
biopsy or excisions are unlikely to be carried out for all clinically benign lesions within a representative population sample.
Therefore, we accepted clinical follow-up of clinically benign lesions as an eligible reference standard, whilst recognising the
risk of differential verification bias (as misclassification rates of histopathology and follow-up will differ) in our quality
assessment of studies.
Additional eligible reference standards included cancer registry follow-up and 'expert opinion' with no histology or clinical
follow-up. Cancer registry follow-up is considered less desirable than active clinical follow-up, as follow-up is not carried out
within the control of the study investigators. Furthermore, if participant-based analyses as opposed to lesion-based analyses
are presented, it may be difficult to determine whether the detection of a malignant lesion during follow-up is the same lesion
that originally tested negative on the index test.
All of the above were considered eligible reference standards with the following caveats:
all study participants with a final diagnosis of the target disorder must have a histological diagnosis, either subsequent to
the application of the index test or after a period of clinical follow-up, and
at least 50% of all participants with benign lesions must have either a histological diagnosis or clinical follow-up to confirm
benignity.
Search methods for identification of studies 
Electronic searches 
The Information Specialist (SB) carried out a comprehensive search for published and unpublished studies. A single large
literature search was conducted to cover all topics in the programme grant (see Appendix 1 for a summary of
reviews included in the programme grant). This allowed for the screening of search results for potentially relevant
papers for all reviews at the same time. A search combining disease-related terms with terms related to the test
names, using both text words and subject headings was formulated. The search strategy was designed to capture
studies evaluating tests for the diagnosis or staging of skin cancer. As the majority of records were related to the
searches for tests for staging of disease, a filter using terms related to cancer staging and to accuracy indices was
applied to the staging test search, to try to eliminate irrelevant studies, for example, those using imaging tests to
assess treatment effectiveness. A sample of 300 records that would be missed by applying this filter was screened
and the filter adjusted to include potentially relevant studies. When piloted on MEDLINE, inclusion of the filter for
the staging tests reduced the overall numbers by around 6000. The final search strategy, incorporating the filter (Appendix
5), was subsequently applied to all bibliographic databases as listed below. The Information Specialist devised the search
strategy, with input from the Information Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August 2016 for relevant published studies:
MEDLINE via OVID (from 1946);
MEDLINE In-Process & Other Non-Indexed Citations via OVID; and
EMBASE via OVID (from 1980).
We searched the following bibliographic databases to 30 August 2016 for relevant published studies:
the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 7, 2016, in the Cochrane Library;
the Cochrane Database of Systematic Reviews (CDSR) Issue 8, 2016 in the Cochrane Library;
Cochrane Database of Abstracts of Reviews of Effects (DARE) Issue 2, 2015;
CRD HTA (Health Technology Assessment) database Issue 3, 2016;
CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO from 1960).
We searched the following databases for relevant unpublished studies:
CPCI (Conference Proceedings Citation Index) via Web of Science™ (from 1990);
Zetoc (from 1993);
SCI Science Citation Index Expanded™ via Web of Science™ (from 1900, using the "Proceedings and Meetings
Abstracts" Limit function).
We searched the following trials registers:
The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov);
NIHR Clinical Research Network Portfolio Database (http://www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/);
The World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/).
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We aimed to identify all relevant studies regardless of language or publication status (published, unpublished, in press, or in
progress). No date limits were applied.
Searching other resources 
We have included information about potentially relevant ongoing studies in the 'Characteristics of ongoing studies' tables. We
have screened relevant systematic reviews identified by the searches for their included primary studies, and included any
missed by our searches. We have checked the reference lists of all included papers, and subject experts within the author
team have reviewed the final list of included studies. No citation searching has been conducted.
Data collection and analysis 
Selection of studies 
Titles and abstracts were screened by at least one author (JDi or NC), with any queries discussed and resolved by
consensus. A pilot screen of 539 MEDLINE references showed good agreement (89% with a kappa of 0.77)
between screeners. Primary test accuracy studies and test accuracy reviews (for scanning of reference lists) of any
test used to investigate suspected melanoma, BCC, or cSCC were included at initial screening. Inclusion criteria (Appendix
6) were applied independently by both a clinical reviewer (from one of a team of twelve clinician reviewers) and a
methodologist reviewer (JDi or NC) to all full text articles, disagreements were solved by discussion or by a third party, in
case no consensus could be reached (JDe, CD, HW, and RM). Authors of eligible studies were contacted when insufficient
data were presented to allow for the construction of 2x2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently extracted data concerning
details of the study design, participants, index test(s) or test combinations and criteria for index test positivity, reference
standards, and data required to populate a 2x2 diagnostic contingency table for each index test using a piloted data
extraction form. Data were extracted at all available index test thresholds. Disagreements were solved by discussion or by a
third party, in case no consensus could be reached (JDe, CD, HW, and RM).
Authors of included studies were contacted where information related to the target condition (in particular to allow the
differentiation of invasive cancers from in situ variants) or diagnostic threshold were missing. Authors of conference abstracts
published from 2013 to 2015 were contacted to ask whether full data were available. If no full paper was identified, we
marked conference abstracts as 'pending' and will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where multiple reports of a primary study were identified, we maximised yield of information by collating all available data.
Where there were inconsistencies in reporting or overlapping study populations, we contacted study authors for clarification
in the first instance. If this contact with authors was unsuccessful, we used the most complete and up-to-date data source
where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using the QUADAS-2 checklist (Whiting 2011), tailored to the
review topic (see Appendix 7). The modified QUADAS-2 tool was piloted on a small number of included full text articles. One
clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently assessed risk of bias and
applicability for the remaining studies; any disagreements were solved by discussion or by a third party, in case no
consensus could be reached (JDe, CD, HW, and RM). Authors were not contacted to clarify any methodological
uncertainties. The methodological quality assessment was therefore of the study as reported and may not always fully reflect
the quality of the study as conducted.
Statistical analysis and data synthesis
Due to paucity of data and between-study heterogeneity in the ultrasound characteristics and measurements that were
investigated, no meta-analysis was undertaken for this review. For the diagnosis of melanoma, any BCCs or invasive cSCCs
that were positively identified in the ‘disease negative’ group were considered as true negative test results rather than as
false positives, on the basis that excision of such lesions would be a positive outcome for the participants concerned. For the
diagnosis of BCC however, any melanomas or cSCCs that were positively identified in the ‘disease negative’ group were
considered false positive results. This decision was taken on the basis that the clinical management of a lesion considered to
be a BCC might be quite different to that for a melanoma or cSCC and could potentially lead to a negative outcome for the
participants concerned, for example if a treatment other than excision was initiated.
Estimates of sensitivity and specificity were plotted on coupled forest plots for each characteristic or threshold under
consideration. Our unit of analysis was the lesion rather than the patient as this was the most common way in which the
primary studies reported data. As most participants have only one lesion to consider at a time, and as both index tests and
reference standards are defined at the lesion level, the results are likely to be similar to those obtained at a participant level.
Data for Doppler ultrasound was included only if reported in combination with HFUS tissue morphological or acoustic
property imaging; the accuracy of Doppler ultrasound alone was not evaluated.
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting the forest plots of sensitivity and specificity. Insufficient
numbers of studies were identified to allow meta-regression to investigate potential sources of heterogeneity.
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Sensitivity analyses
No sensitivity analyses were conducted due to lack of data.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias for diagnostic accuracy studies and the inadequacy
of tests for detecting funnel plot asymmetry (Deeks 2005), no tests to detect publication bias were performed.
Results 
Results of the search
A total of 34,347 unique references were identified and screened for inclusion. Of these, 1051 full text papers were reviewed
for eligibility for any one of the suite of reviews of tests to assist in the diagnosis of melanoma or keratinocyte skin cancer. Of
the 1051 full text papers assessed, 848 were excluded from all reviews in our series and 203 publications were included (see
Figure 6 PRISMA flow diagram of search and eligibility results).
Of the 41 studies tagged as potentially eligible for this review of HFUS, six were included and copies of two could not be
obtained from the British Library (Bens 2015; Nitsche 1992). Exclusions were due to the use of ineligible index tests (n = 16)
(for example: evaluations of Doppler ultrasound (n = 9) or studies using ultrasound transducers with centre frequency less
than 20 MHz (n = 7)); ineligible study populations (n = 4) (for example, recruiting only malignant lesions (n = 2) or including
lesions that were not suspicious for skin cancer (n = 2)); ineligible definition of the target condition (n = 8) (including those
identifying lesion thickness (n = 4), surgical margins (n = 1) or melanoma metastases (n = 2), or where lesions such as
dermatofibroma or Bowen's disease were considered disease positive (n = 1)); and inadequate sample size (n = 1). A list of
the 33 studies excluded from this review with reasons for exclusion is provided in Characteristics of excluded studies, with a
list of all studies excluded from the full series of reviews available as a separate pdf. The authors of one publication were
contacted for the purposes of this review, however they were unable to provide the additional data needed to allow the study
to be included.
This review reports on a total of six cohorts of lesions published in six study publications, and providing 29 datasets, 20 for
melanoma and 9 for BCC. No data relating to the diagnosis of cSCC were identified.
Studies included four case series of patients with pigmented lesions (Bessoud 2003; Clement 2001; Dummer 1995)
or lesions described as suspicious for melanomas or BCC (Lassau 1997) and two case control type studies (Harland 2000; 
Rallan 2007) which included pigmented lesions with specific confirmed diagnoses (confirmed melanomas, seborrhoeic
keratosis or benign nevi). The Bessoud 2003 paper is from the same institution and has overlapping authorship with Lassau
1997, and may have overlap in study participants. Only Rallan 2007 clearly described the basis for referral or selection for
ultrasound examination, randomly selecting lesions referred from primary care due to suspicion of melanoma. Clement 2001
described the clinical diagnosis as ‘hesitant’ for more than half of included lesions, none of the other studies gave any
indication as to the equivocal nature or difficulty of diagnosis of the lesions included. The number of included patients ranged
from 70 to 160 (reported in four studies) and lesions from 54 to 792. Patient characteristics such as age and gender were
reported in only three studies.
Data allowing the calculation of the accuracy of ultrasound for the detection of melanoma were reported in all studies apart
from Clement 2001 which focused primarily on the detection of BCC; two other studies also report data for detection
of BCC (Dummer 1995; Lassau 1997). The prevalence of melanoma in the study samples ranged from 14% to 58%, and
appeared to be restricted to invasive melanoma only in Dummer 1995 and Lassau 1997. The prevalence of BCC
was 8% (Dummer 1995), 17% (Clement 2001) and 49% (Lassau 1997). In all studies apart from Lassau 1997 and Bessoud
2003, seborrhoeic keratosis made up at least 25% of the disease negative groups, ranging as high as 66% in Harland 2000
who selected to study seborrhoeic keratosis versus melanoma.
All six studies used 20 MHz ultrasound scanners with axial resolutions of 50 to 80 µm (Dummer 1995; Lassau 1997; 
Clement 2001; Bessoud 2003; Harland 2000; Rallan 2007) and lateral resolutions of about 100 µm (Lassau 1997, Clement
2001; Bessoud 2003; Rallan 2007) to 300 µm (Harland 2000). Typically it was not clear how the resolution values were
obtained and, from the appearances of example images in the papers, the instrumentation employed varied greatly in terms
of other diagnostically important imaging performance properties such as signal dynamic range and signal to noise level,
which were not reported. In some cases such performance appeared to be poor, providing little or no lesion internal detail
compared with similar lesions on other systems. None of the studies described the qualifications or experience of the
clinician carrying out and interpreting the ultrasound and none reported whether the clinical or dermoscopic diagnosis of the
lesion was provided to aid test interpretation.
Three studies explicitly set out to establish the diagnostic accuracy of HFUS for the differentiation of melanomas
from other skin lesions (Bessoud 2003; Harland 2000; Rallan 2007); the remaining three studies did not set out to
evaluate test accuracy but presented data for the presence or absence of particular ultrasound characteristics that
could be extracted into 2x2 contingency tables (Clement 2001; Dummer 1995; Lassau 1997). Qualitative HFUS
characteristics that were considered related to echogenicity, homogeneity of appearance and definition of margins (Bessoud
2003; Clement 2001; Dummer 1995; Lassau 1997). Four studies presented data for qualitative assessment of the
presence or absence of particular structural characteristics (including echogenicity, homogeneity of appearance and
definition of margins) on the HFUS image either alone (Dummer 1995; Lassau 1997; Clement 2001; Bessoud 2003)
or in combination with Doppler ultrasound assessment of vascularity (Lassau 1997; Clement 2001; Bessoud 2003).
The remaining two studies examined different approaches to quantitatively interpret ultrasound findings. Harland 2000
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attempted to classify lesions based on objective quantifications of the extent of ultrasound shadowing and the strength of the
ultrasound entry echo to differentiate between melanoma and seborrhoeic keratosis, based on the dermal echogenicity ratio
(DER) and presence of a thickened entry echo line (EEL) respectively. Rallan 2007 further developed this work with a
prototype 3D HFUS C-scan and “reflex transmission” imaging system to evaluate these features and make ultrasound
images easier for dermatologists to interpret. Three en face ultrasound images are produced: a reflex transmission
image (RTI), a lesional backscatter image (LBI) and an entry echo image (EEI), which relate to objectively quantified
lesion attenuation properties, intralesional sound reflection and surface sound reflectance characteristics, respectively.
For each image two quantitative features were estimated (contrast and heterogeneity) and compared between lesion
groups (melanoma versus seborrhoeic keratosis, and melanoma versus other benign pigmented lesions). Mean RTI
contrast, LBI relative heterogeneity, and EEI relative heterogeneity were each significantly different between
melanoma and seborrhoeic keratosis and between melanoma and benign naevi; these three features were combined
using an ‘or’ rule with specificity estimated at 100% sensitivity (Rallan 2007). The required values for each of the three
parameters to be considered ‘positive’ were reported graphically but not numerically (Rallan 2007).
Three studies using qualitative HFUS interpretation reported the exclusion of lesions not visualised by ultrasound; 10% in
Lassau 1997 (including 3 melanomas), 12% in Bessoud 2003 (including for 5 melanomas), and 22% in Clement 2001
(including 5 melanomas). In all studies the reference standard diagnosis was made by histology alone (i.e. all
lesions either excised or biopsied). Histological diagnosis was based on excisional biopsy (Dummer 1995), surgical
resection or excision (Lassau 1997; Bessoud 2003; Harland 2000; Rallan 2007) and either approach (Clement 2001).
Methodological quality of included studies
The overall methodological quality of all included studies (n = 6) is summarized in Figure 7 and Figure 8.
A third of studies (n = 2) were at high risk of bias for participant selection due to individual studies having been
designed to selectively include participants with particular histological lesion types (Harland 2000; Rallan 2007). Five
studies did not clearly describe participant recruitment as random or consecutive and four did not clearly report any
exclusion criteria. One study was judged as low concern for applicability of participants and setting (Clement 2001).
Five studies were judged as having high (n = 4) or unclear (Dummer 1995) concern for applicability of participants due to
unrepresentative patient samples (n = 3), inclusion of multiple lesions per patient (n = 1), or providing insufficient information
on which to make a judgement (n = 2). All studies included only lesions selected for excision.
Only one study was at low risk of bias in the index test domain. Ultrasound was considered to have been interpreted
prior to the histological reference standard in all studies, but only one clearly reported prior specification of the
diagnostic threshold or ultrasound characteristics used to differentiate melanomas from other lesions (Bessoud 2003
). The other studies were all rated as high risk for this item either because they did not clearly set out to examine the
accuracy of HFUS (Clement 2001; Dummer 1995; Lassau 1997) or because they deliberately set their thresholds to
achieve 100% sensitivity (Harland 2000; Rallan 2007). A third of studies were at high concerns around the
applicability of the index test, due to the use of a prototype ultrasound device on one study (Harland 2000) and a
relatively experimental approach to the index test in another (Rallan 2007). All studies clearly described the criteria or
diagnostic thresholds used, but no study provided information on the expertise and experience of the test operator or
sonographer.
All studies reported the use of an acceptable reference standard, but only one clearly reported blinding of the
reference standard to the ultrasound result (Harland 2000), and none of the studies reported blinding to the referral diagnosis
(based on clinical examination or dermoscopy). For the applicability of the reference standard, no study reported using expert
diagnosis to provide the final diagnosis of any lesion but only one reported histopathology interpretation by an experienced
histopathologist or by a dermatopathologist.
The same reference standard was used in all participants in all studies and two were unclear on the interval
between the application of the index test and excision for histology (Bessoud 2003; Harland 2000). Three studies
reported exclusions due to lesions not being visualised on ultrasound (Bessoud 2003; Clement 2001; Lassau 1997);
however, all three provided a breakdown of the final histologic diagnosis for these lesions and were therefore judged
as low risk on the flow and timing domain. Three studies did not report any exclusions due to lack of visualisation of
lesions (Dummer 1995; Harland 2000; Rallan 2007). Two of these allowed the ultrasound features employed to be
measured regardless of whether the lesions were visualised or not and were judged as having low risk of bias on this
item (Rallan 2007; Harland 2000).
Findings
Lack of data and between study variation in populations, ultrasound techniques and characteristics and measurements
investigated precluded meta-analysis. Study results are summarised below according to target condition: melanoma or BCC.
No data on the identification of cSCC was found. Summary details are provided in Appendix 8; forest plots of available study
data are given in Figure 9 (HFUS for differentiation of melanoma), Figure 10 (for HFUS combined with Doppler US for
melanoma) and Figure 11 (HFUS for differentiation of BCC).
Detection of invasive melanoma or melanoma in situ
Combinations of subjective assessments of HFUS features
HFUS data related to the qualitative assessment of the presence or absence of different combinations of lesion
morphological and structural characteristics as an indicator of melanoma could be extracted from three studies (Bessoud
2003; Dummer 1995; Lassau 1997), one of which set out to assess the diagnostic accuracy of these characteristics
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for the differentiation of melanoma from other lesions (Bessoud 2003) (Figure 9; Appendix 8).
Dummer 1995 reported recruitment of a series of 792 pigmented lesions with a range of final diagnoses including melanoma
(14%), BCC (8%), benign naevi (39%), seborrhoeic keratosis (27%), and dermatofibroma or angioma (13%). Sensitivities
and specificities estimated from the data presented ranged from 83% (95% CI 75% to 90%) and 64% (95% CI 60% to 87%)
for hypoechoic and homogenous lesions to 91% (95% CI 84% to 95%) and 22% (95% CI 19% to 26%) for hypoechoic
lesions with sharp lateral margins. For each of the combinations of characteristics examined in this study a number of BCCs
were found to be ‘test positive’, i.e. displaying the characteristics under consideration. As per our protocol, these ‘false
positive’ BCCs were reclassified as true negative test results (increasing specificity) on the basis that a positive test result
leading to the excision of these BCCs would not be a negative patient outcome. The number of BCCs that we artificially
reclassified as true negative despite the presence of the HFUS image features of interest ranged from 5 (for echo poor
lesions with homogenous internal echoes) to 57 (for echo poor lesions with sharp basal margins).
Data for the presence of hypoechoic, homogenous, well-defined lesions were presented in Bessoud 2003 and Lassau 1997,
both of which also reported results for Doppler ultrasound that could be combined with HFUS data. Bessoud 2003 included a
series of 114 pigmented lesions (7 of which did not undergo Doppler ultrasound); included lesions were primarily invasive
melanomas (57%) or benign naevi (29%) with smaller percentages of BCC (4%), seborrhoeic keratosis (4%) and other
benign lesions. Lassau 1997 included 70 lesions clinically suspected of being melanoma (n = 38) or BCC (n = 32); seven
lesions could not be visualised on ultrasound and were excluded leaving 19 (27%) invasive melanoma, 31 (44%) BCC, 1
neurosarcoma and 12 (17%) benign naevi (3 of the 7 lesions not visualised on HFUS were melanomas).
The sensitivity of the combined HFUS characteristics was 100% in both studies with specificities of 33% (95% CI 20% to
48%) in Bessoud 2003 (114 lesions; 65 melanomas) and 73% (95% CI 57% to 85%) in Lassau 1997 (63 lesions; 19
melanomas) (lower limits of the 95% CIs for sensitivities were 94% and 82% respectively). Excluding BCCs from Lassau
1997 resulted in a specificity of 8% (95% CI 0% to 36%) (32 lesions; 19 melanomas); the 12 benign naevi all being
considered hypoechoic, homogenous and well defined. Both studies reported all BCCs as ‘negative’ on ultrasound
(i.e. absence of investigated characteristics) (Bessoud 2003; Lassau 1997). Both studies also reported five
melanomas amongst the lesions not visualised by ultrasound (Appendix 8).
Combinations of subjective assessments of HFUS features with Doppler US
Using data presented in Lassau 1997 for the presence of hypoechoic, homogenous, and well defined lesions on HFUS
with the presence of intratumoural vessels on Doppler ultrasound (on an either or basis) makes no difference to the
sensitivity and specificity achieved using HFUS alone for the discrimination of invasive melanoma (n = 19) from all
other included lesions (n = 44). Only three melanomas (already picked up as test ‘positive’ on HFUS) displayed any
evidence of vascularity on Doppler (sensitivity 100% (95% CI 82% to 100%) and specificity 73% (95% CI 57% to
85%)) (Figure 10). The HFUS and Doppler characteristics can be combined on an and basis for both Bessoud 2003 and
Lassau 1997 (lesions that were hypoechoic, homogenous and well defined and exhibited intra-lesional vessels on Doppler
considered test positive): sensitivities were 34% (95% CI 22% to 47%; n = 65 melanomas) and 16% (95% CI 3% to 40%; n =
19 melanomas) respectively with specificities of 100% (95% CI 92% to 100%) for both studies (n = 45 and n = 44).
Quantitative assessment of HFUS features
Two studies (Harland 2000; Rallan 2007) reported quantitative assessments of the ultrasound image using the strength and
heterogeneity of ultrasound shadowing and the strength and heterogeneity of the ultrasound surface entry echo. Both studies
included only melanoma, melanoma in situ, benign naevi or seborrhoeic keratosis (n = 19, 6, 15, 29 in Harland 2000; and n =
14, 11, 38, 24 in Rallan 2007). The main comparison in Harland 2000 was between melanoma and seborrhoeic
keratosis (benign naevi excluded). Setting the DER at <3 to ensure sensitivity of 100% produced a specificity of 79%
(95% CI 60% to 92%); the absence of an EEL resulted in sensitivity of 96% (95% CI 80% to 100%) and specificity 90%
(95% CI 73% to 98%) for the same comparison. Combining the two characteristics on an either or basis (such that
sensitivity was 100%), increased specificity to 93% (95% CI 77% to 99%) for discrimination of melanoma from
seborrhoeic keratosis (Figure 9). Of the 15 benign naevi in this study, six were reported to have characteristics associated
with EEL enhancement (or EEE) suggesting that nine would be considered ‘test positive’ (absence of an EEL); inclusion of
these lesions as disease negative would reduce the observed specificity.
Rallan 2007’s work on a prototype 3D HFUS C-scan with “reflex transmission” imaging, found significant differences in
the mean values of RTI contrast, LBI relative heterogeneity, and EEI relative heterogeneity between melanoma and
seborrhoeic keratosis and between melanoma and benign naevi. When these three features were combined using an
‘or’ rule with sensitivity for melanoma discrimination of 100% (95% CI 86% to 100%) resulting specificity was 65%
(95% CI 51% to 76%) (Figure 9).
Detection of BCC
Combinations of subjective assessments of HFUS features
Three studies including series of pigmented lesions (Clement 2001; Dummer 1995) or including lesions suspicious for
either melanoma or for BCC (Lassau 1997) reported data that could be used to derive the accuracy of ultrasound
characteristics for BCC, two of which also reported data for melanoma (Dummer 1995; Lassau 1997). None of the three
studies set out to establish the accuracy of the reported ultrasound characteristics. Clement 2001 included a series of 176
pigmented lesions, 38 of which were not visualised on ultrasound (including 5 melanomas); the remaining 138 lesions
included one invasive melanoma, 23 (17%) BCC, 61 (44%) benign naevi, and 29 (21%) seborrhoeic keratoses, amongst
others.
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Using hypoechoic and homogenous appearance as a positive indicator for BCC, sensitivity and specificity were 91% (95% CI
72% to 99%) and 14% (95% CI 8% to 22%) for Clement 2001 (138 lesions; 23 BCC) and were 8% (95% CI 3% to 17%) and
54% (95% CI 50% to 57%) in Dummer 1995 (792 lesions; 65 BCC) (Figure 11).
Considering lesions that were hypoechoic and well defined as positive for BCC, resulted in sensitivity of 83% (95% CI 61% to
95%) and specificity 32% (95% CI 24% to 42%) in Clement 2001. Dummer 1995 reported numbers of lesions with sharp
basal margins and with sharp lateral margins. Considering lesions that were hypoechoic with sharp basal margins as positive
for BCC, resulted in sensitivity 86% (95% CI 75% to 93%) and specificity 20% (95% CI 17% to 23%); considering lesions that
were hypoechoic with sharp lateral margins as positive for BCC, resulted in sensitivity 42% (95% CI 29% to 54%) and
specificity 13% (95% CI 11% to 16%).
Finally, data from Lassau 1997 could be derived to consider hypoechoic, homogenous and well defined lesions as BCC (i.e.
the same characteristics previously considered to be positive indicators for melanoma); this combination resulted in
sensitivity of 0% (95% CI 0% to 11%) and specificity of 3% (95% CI 0% to 16%) (63 lesions; 31 BCCs; Figure 11). All
BCCs were reportedly hypoechoic but with a heterogeneous echostructure and lateral extensions with irregular
margins, i.e. negative on two of the characteristics considered (Lassau 1997). If one instead considers the presence of a
heterogeneous echostructure and lateral extensions with irregular margins to be positive indicators of BCC (i.e. reversing the
2x2 contingency table), the resulting sensitivity is 100% (95% CI 89% to 100%) and specificity 97% (95% CI 84% to 100%),
with no melanomas and none of the benign naevi displaying these characteristics. Bessoud 2003 also reported all four
included BCCs to be heterogenous and poorly defined, however a further 12 lesions including keratosis, melanosis and
neurosarcoma also demonstrated these characteristics.
Combinations of subjective assessments of HFUS features with Doppler US
Two of the studies reporting data for BCC also employed Doppler US in combination with HFUS (Lassau 1997; Clement
2001). One study allowed extraction of accuracy data only for the detection of melanoma (melanoma versus benign
naevi) (Lassau 1997), while for the other, consideration of lesions that were hyperechoic on HFUS and displaying
vascularity on Doppler produced a sensitivity of 0% (95% CI 0% to 15%) and specificity 89% (95% CI 81% to 94%) (
Clement 2001). Considering the absence of these characteristics as indicative of BCC (i.e. hypoechoic with no vascularity on
Doppler) would reverse these estimates, giving sensitivity of 100% and specificity 11%.
Investigations of heterogeneity
We were unable to undertake formal investigations of heterogeneity due to insufficient study numbers.
Discussion 
Summary of main results
This review aimed to assess the accuracy of high frequency ultrasound as an aid to diagnosing melanoma, BCC
and cSCC in adults. No eligible data on cSCC were identified. We included six studies evaluating high frequency
ultrasound, three of which also evaluated Doppler ultrasound (Summary of findings table 1).
Studies were generally poorly reported such that methodological quality and applicability of findings could not be clearly
judged; this was in part due to the fact that half of the studies did not set out to establish test accuracy. Particularly high
concerns were noted in regard to the selection of study participants, with high proportions of malignant lesions and an
unrepresentative spectrum of disease in the disease negative groups. The clinical pathway and referral process for
ultrasound imaging was not always well described. All studies used 20MHz ultrasound devices at a range of resolutions and
a number of different qualitative and quantitative thresholds, some of which were clearly data driven or not pre-specified. In
half of the studies (all using qualitative or subjective assessments of HFUS images), a considerable proportion of lesions
were excluded by the study authors because the lesions were not visualised by ultrasound. It is not clear from these studies
whether this should be considered a failure of the test or whether the lack of visualisation of a lesion on HFUS provides
further diagnostic information that may assist in the differential diagnosis. Studies applying quantitative interpretations of
HFUS allowed some ultrasound features to be measured regardless of lesion ‘visibility’. No information was provided
regarding the clinicians undertaking and interpreting the tests, limiting the generalisability of results particularly for those
relying on qualitative interpretation of HFUS features. The final diagnoses were established by histology in all studies;
blinding to the ultrasound result or referral diagnosis was reported in only one study. Sources of heterogeneity included
patient selection, ultrasound techniques, test thresholds, prior testing and blinding.
For the detection of melanoma, derived sensitivities were at least 83% (95% CI 75% to 90%), with the combination of three
qualitative features (lesions appearing hypoechoic, homogenous and well defined) and quantitative assessments of images
demonstrating 100% sensitivity in four studies (the widest 95% CI being 80% to 100%), although in two of these the decision
thresholds were deliberately set to achieve 100% sensitivity in order to discover resulting specificity. Between three and five
melanomas were amongst the lesions not visualised by the HFUS in three studies, no index test ‘failures’ were reported by
the two studies assessing quantitative metrics. Specificities varied from 8% (95% CI 0% to 36%) to 73% (95% CI 57% to
85%) for qualitative characteristics, all of which included BCC in the disease negative group which tends to increase
specificity, and from 65% (95% CI 51% to 76%) to 90% (95% CI 73% to 98%) for quantitative measurements, none of which
included BCC in the disease absent group. For the detection of BCC, sensitivities and specificities were highly variable,
making summary statements difficult. One study suggested that the presence of heterogeneity and poorly defined margins
might differentiate BCCs from melanomas and benign naevi, although another identified other lesions demonstrating similar
characteristics that might limit their usefulness in a more widely defined population.
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Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehensive electronic literature search, systematic review methods
including double extraction of papers by both clinicians and methodologists, and contact with authors to allow study inclusion
or clarify data. A clear analysis structure was planned to allow test accuracy in different study populations to be estimated
and a detailed and replicable analysis of methodologic quality was undertaken.
The main concerns for the review are a result of the poor reporting of primary studies and the fact that the studies were not
all designed as test accuracy studies; in half of included studies, data to allow the estimation of sensitivity and specificity was
derived from the information on image descriptions presented by the study authors. All three studies using qualitative
interpretation of HFUS reported that a number of lesions (including some melanomas) had to be excluded because they
could not be visualised, resulting in an over-estimation of sensitivity for the characteristics assessed. Two of the remaining
studies using quantitative HFUS metrics and methodology allowed inclusion of all lesions regardless of whether the lesions
were visualised, however.
When estimating accuracy for the diagnosis of melanoma, any correctly identified BCCs were classed as true negative
results as opposed to false positives, on the basis that removal of a BCC in the attempt to identify melanomas would not be a
negative consequence of the test. This will have the effect of increasing specificity compared to studies from which BCCs
had been excluded. When estimating accuracy for the diagnosis of BCC however, any other skin cancers that were
incorrectly identified as BCC (e.g. melanomas or cSCCs) were considered false positive results, as the subsequent
management of a BCC can be quite different to that of a melanoma or SCC and it is important that a test can accurately
differentiate between malignancies.
Applicability of findings to the review question
The data included in this review came from preliminary exploratory studies and are unlikely to be generally applicable to
predicting the diagnostic accuracies that would be expected in a standard clinical practice where people present with a broad
range of different lesion types. Narrow definitions of the eligible study populations, lack of clarity regarding the patient
pathway and any prior testing, and wide variation in the type and performance of the HFUS equipment employed as well as
in the method used for image feature scoring, restricts generalisation and applicability. It is not always clear whether the
particular test methods used could be transferred to a clinical setting.
Authors' conclusions 
Implications for practice 
No summary estimates of test accuracy could be produced to answer the research question for this review. High frequency
ultrasound may prove to be an additional tool to assist in the differentiation of melanoma from other lesions however the
current evidence is based on participants with highly selected lesion types and it is unclear how their results would translate
in clinical practice. The lack of visualisation of lesions on HFUS is potentially a major disadvantage unless the lack of
visualisation has a clear interpretation which can be used to inform management decisions, or ultrasound metrics that do not
depend on lesion visualisation can be employed, or ultrasound visualisation can be improved with equipment development.
Given the between study heterogeneity, unclear to low methodological quality and applicability of findings, and limited
volume of evidence, no implications for practice can be drawn. The main value of the preliminary studies included in this
review may be in provision of guidance on the possible components of diagnostic rules for the diagnosis of melanoma or of
BCC using HFUS that require future evaluation.
Implications for research 
Prospective evaluation of high frequency ultrasound added to visual inspection and dermoscopy alone in a standard health
care setting would be required for a full and proper evaluation of accuracy. A clearly defined and representative population of
participants with a range of different lesion types is needed to establish the participant groups to whom study results can be
applied in practice. HFUS technology continues to be developed therefore it is important that current equipment is employed,
using compatible systems across centres, appropriate harmonisation in cross-centre training and, where possible, the use of
objective quantitative diagnostic image features so as to minimise exclusions (due to lack of visualisation) and inter-observer
variability.
Prospective recruitment of a consecutive series of participants, with double-blinding between test interpretation and
the reference standard diagnosis, and with pre-specified and clearly defined diagnostic rules for determining the
presence or absence of disease are necessary and easily achieved. Systematic follow-up of non-excised lesions
avoids over-reliance on a histological reference standard and allows results to be more generalisable to routine
practice. A standardised approach to diagnosis, and clear identification of the qualifications and level of observer
training and experience required to achieve good results is also required. A multi-centred approach would allow
confirmation that results are replicable across centres and that the technology can be implemented across a health
service. Any future research study needs to be clear about the diagnostic pathway followed by study participants
prior to study enrolment, and reporting should conform to the updated Standards for Reporting of Diagnostic
Accuracy (STARD) guideline (Bossuyt 2015).
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Differences between protocol and review 
Due to the small number of studies available, a single review has been produced that evaluates the accuracy of HFUS in all
skin cancers; this replaces the two reviews intended in the protocols to address cutaneous melanoma and keratinocyte
cancers.
This single review includes three primary objectives related to the detection of each of: melanoma, BCC and cSCC. For the
detection of melanoma, the primary objectives and primary target condition have been changed from detection of invasive
melanoma alone, to the detection of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants, as the
latter is more clinically relevant to the practicing clinician. An additional secondary objective was added to allow the
evaluation of Doppler ultrasound in combination with high frequency ultrasound for skin cancer diagnosis.
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Heterogeneity investigations and sensitivity analyses were limited by the data available.
Due to the early phase nature of HFUS diagnosis for skin cancer, this text from the protocol "we will include studies
developing new algorithms or methods of diagnosis (i.e. derivation studies) if they use a separate independent 'test set'
of participants or images to evaluate the new approach. We will also include studies using other forms of cross
validation, such as 'leave-one-out' cross-validation (Efron 1983). We will note for future reference (but not extract) any data
on the accuracy of lesion characteristics individually, e.g. the presence or absence of a pigment network or detection of
asymmetry" has been replaced with "Studies should ideally evaluate a predefined 'rule' or algorithm describing combinations
of ultrasound characteristics that determine the presence or absence of melanoma, BCC or cSCC. However, as HFUS is in a
relatively early phase of development, studies were included if 2x2 contingency table data could be extracted based on the
presence or absence of at least two ultrasound features related to tissue morphology or acoustic properties, for example
echogenicity, homogeneity of appearance and definition of margins. Studies attempting to quantify HFUS parameters were
also eligible for inclusion. There was no requirement for studies to have explicitly set out to estimate the diagnostic accuracy
of the parameters assessed."
Although we extracted any reporting of special interest or accreditation in skin cancer according to observer expertise, we
were unable to analyse the effect on accuracy.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g.
British Association of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European
Academy of Dermatology and Venereology Meeting, Society for Melanoma Research Congress, World Congress of
Dermatology, European Association of Dermato Oncology); however, due to volume of evidence retrieved from database
searches and time restrictions we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic and to cover both melanoma
and keratinocyte skin cancers. In terms of analysis, restriction to analysis of per patient data was not performed due to lack
of data. Sensitivity analyses were not performed as planned due to lack of data.
Published notes 
Characteristics of studies
Characteristics of included studies 
Bessoud 2003
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: NR; 4 year period
Country: France
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with pigmented skin
lesions referred from the Dermatology Department
to the Ultrasound Unit
Setting: Secondary
Prior testing: Referred from Dermatology; basis for
referral not described
Exclusion criteria: None reported
Sample size (patients): No. eligible: 111
Sample size (lesions): No. eligible: 130; No.
included: 114 (107 for Doppler)
Participant characteristics: Mean age: 55.3 (SD 18;
6 to 92 yrs). Male: 47 (42%)
Lesion characteristics: For melanomas visualised on
ultrasound (n=65), thickness ranged from 0.15 to 8
mm on histology.
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Ultrasound: High frequency (20MHz) and Colour Doppler (7MHz)
Test detail: AU 4 or AU 5 Idea (Esaote-Biomedica, Genova, Italy) with a 20-MHz annular probe (axial
resolution 80 µm and lateral resolution 100 µm) and 13-MHz linear electronic probe (axial resolution
200 µm and lateral resolution 400 µm); Colour Doppler adjustments included a pulse-repetition
frequency (PRF) of 750 Hz to 1 kHz, with a 50-Hz filter and nine to 16 images per second
Method of diagnosis: In person diagnosis
Prior test data available: Unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: HFUS - Hypoechoic, homogenous and well defined margins; HFUS plus Doppler
- hypoechoic, homogenous and well defined plus presence of intra-lesional vessels
Diagnosis based on: Unclear whether single or multiple observers (n=NR)
Observer qualifications: Not reported
Experience in practice: Not described
Experience with index test: Not described
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: None provided
Disease positive: 70; Disease negative: 60
Target condition (Final diagnoses) 
Melanoma (invasive or in situ): 65; BCC: 4; 1
neurosarcoma
'Benign' diagnoses: 33 benign nevi, 5 seborrhoeic
keratosis, 3 melanosis, 1 thrombosing capillaritis, 1
histiocytofibroma, 1 lentigo
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge
of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Index test to reference standard interval: Not
described
Exclusions: 16 lesions 'unseen' on US were
excluded (5 melanoma, 1 lentigo, and 10
benign nevi) leaving 114 lesions reported for
HFUS, 107 of which underwent Doppler
ultrasound
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Clement 2001
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: November 1998 to
July 1999
Country: France
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with pigmented skin
tumours including melanocytic and non melanocytic
examined before resection; clinical diagnoses
described as 'hesitant' (NB translation from French)
for more than half of lesions
Setting: Secondary
Prior testing: NR; basis for referral not described
Exclusion criteria: Difficult to reach lesions (two
dermal nevus - one at the internal angle of the eye
and the other between the toes)
Sample size (patients): No. eligible: 160
Sample size (lesions): No. eligible: 176; No.
included: 138
Participant characteristics: For full sample - mean
age: 52.7 years (18 to 90 years). Male: 74 (46%)
Lesion characteristics: 5 melanomas not visualised
on ultrasound; all had Breslow index less than 0.35
mm
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? Low concern
Index Test
Index tests
Ultrasound: High frequency (20MHz) and Colour Doppler (7 MHz)
Test detail: used an annular linear scanning probe with theoretical spatial resolution of 80 μm (axial)
and 100 μm (lateral); equipped with an ultrasonic beam variable electronics management system to
obtain an optimal focal area at penetration depths of 12.5 and 19 mm; for Doppler, a linear electronic
probe (frequency of ultrasound: 13 MHz, axial theoretical spatial resolution: 200 μm, lateral: 400 μm)
was used
Method of diagnosis: In person diagnosis
Prior test data available: Unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: HFUS - hypoechoic; hypoechoic and homogenous; hypoechoic and well defined;
HFUS + Doppler - hypoechoic and presence of vascularity
Diagnosis based on: Unclear whether single or multiple observers (n=NR)
Observer qualifications: Not reported
Experience in practice: Not described
Experience with index test: Not described
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: None provided
Disease positive: 24; Disease negative: 115
Target condition (Final diagnoses) 
Melanoma (invasive or in situ): 1; BCC: 23; 6 melanoma
metastases (considered disease negative for this
review)
'Benign' diagnoses: 61 benign nevi, 29 seborrhoeic
keratosis, 11 histiocytofibroma, 7 angioma
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Unclear
Were the reference standard results interpreted without knowledge
of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Index test to reference standard interval:
Consecutive; each lesion scanned immediately
before its biopsy or surgical excision, or both
Exclusions: 36 lesions were not visualised on
US and were excluded (including 5
melanomas in the horizontal growth phase
(Clark levels I and II, Breslow index less than
0.35 mm)) leaving 138 lesions reported for
HFUS
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Dummer 1995
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear
Period of data collection: NR
Country: Germany
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with pigmented skin
lesions referred from the outpatient clinic to the
Department of Dermatology
Setting: Secondary
Prior testing: All patients underwent physical
examination and 508 underwent dermoscopy before
HFUS; basis for referral not described
Exclusion criteria: None reported
Sample size (patients): No. eligible: NR
Sample size (lesions): No. eligible: 792; No.
included:
Participant characteristics: Mean age: NR Male: NR
Lesion characteristics: For the 108 melanomas,
Breslow thickness was <0.76mm in 45; 0.76 to
1.5mm in 26; 1.5 to 4.0mm in 24; and >4.0mm in 12.
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? Unclear
Index Test
Index tests
Ultrasound: High frequency (20MHz) 
Test detail: DUB 20 (Taberna pro Medicum, Luneburg, Germany) at axial resolution 80 μm and lateral
resolution 200 μm. Several sonographic scans were carried out perpendicular to the previous ones in
parallel planes for each individual tumour; B-scan section corresponds to a width of 12 .8 mm and a
depth of 7.5 mm
Method of diagnosis: In person diagnosis
Prior test data available: Unclear whether clinical or dermoscopy diagnosis provided to sonographer;
no data available for overall dermoscopy diagnosis
Diagnostic threshold: echo poor (hypoechoic); echo poor with no internal echoes; echo poor with sharp
basal margins; echo poor with sharp lateral margins
Diagnosis based on: Unclear whether single or multiple observers (n=NR)
Observer qualifications: Not reported
Experience in practice: Not described
Experience with index test: Not described
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis alone
Details: Excisional biopsy; reviewed by the
dermatopathology staff at the departments of
dermatology (Universities of Wurzburg and Munich
[Germany]) and 78 lesions additionally reviewed by the
dermatopathology staff of the department of
dermatology, University Hospital, Zurich, Switzerland.
Disease positive: 173; Disease negative: 619
Target condition (Final diagnoses) 
Melanoma (invasive or in situ): 108; BCC: 65;
'Benign' diagnoses: 307 benign nevi, 211 seborrhoeic
keratosis, 47 angioma, and 54 dermatofibroma
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Were the reference standard results interpreted without
knowledge of the referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Index test to reference standard interval:
Appears consecutive; The patients were
subjected to ELM and ultrasound examination.
After excisional biopsy, the correlation
between clinical, ELM, sonographic, and
histologic diagnosis was established.
Exclusions: No exclusions due to lack of
visualisation on ultrasound.
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Unclear
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Harland 2000
Patient Selection
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A. Risk of Bias
Patient Sampling
Study design: Case control (only specific
diagnoses included)
Data collection: Unclear
Period of data collection: NR
Country: UK
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with pigmented lesions
with specific presumptive clinical diagnoses
(seborrhoeic keratosis, benign naevi or cutaneous
malignant melanoma) recruited from a pigmented
lesion clinic; the referring general practitioner had
considered the diagnosis of melanoma for each
lesion.
Setting: Specialist clinic
Prior testing: Clinical diagnosis made at PLC
Exclusion criteria: Lesions with macroscopic
ulceration
Sample size (patients): No. eligible: NR
Sample size (lesions): No. eligible: NR; No.
included: 69
Participant characteristics: Mean age: NR. Male:
NR.
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Ultrasound: High frequency (20MHz) 
Test detail: Dermascan-CTM 20-MHz B-scanner (Cortex Technology, ApS, Hadsund, Denmark); axial
resolution of 50 μm and a lateral resolution of 300 μm; in vivo slice 22´4 mm width, 13´4 mm depth
(6´7 mm with zoom factor 2) and 200 μm thickness. Scanner described as "US prototype with a large
unwieldy scanner head, such that certain sites, such as the inner canthus, are inaccessible to
examination. However, the aim of this pilot study was not to evaluate practicality of clinical use."
Method of diagnosis: In person diagnosis
Prior test data available: Unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: DER - dermal echogenicity ratio < 3 set to ensure sensitivity of 100% for
melanoma; EEL - absence of entry echo line (documented as either equivalent to perilesional skin
(nonenhanced) or as broadened); DER <3 or absence of EEL
Diagnosis based on: Unclear whether single or multiple observers (n=NR)
Observer qualifications: Not reported
Experience in practice: Not described
Experience with index test: Not described
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: Histological evaluation was
performed without knowledge of the
ultrasound findings. Histological sections of
tumours were prepared in the same plane
as the B-scans, both being centred upon the
transverse reference line.
Target condition (Final diagnoses) 
Melanoma (invasive): 19. Melanoma in situ:
6. BCC: 0.
'Benign' diagnoses: 15 benign nevi, 29
seborrhoeic keratosis
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Index test to reference standard interval: Not
described
Exclusions: No exclusions due to lack of
visualisation on ultrasound.
Was there an appropriate interval between index test and reference
standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Unclear risk
Notes
Notes -
 
Lassau 1997
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: NR
Country: France
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients with skin lesions clinically
suspected of being either melanoma or BCC and
scheduled for resection; includes only very specific
lesion groups (MM, BCC, and benign nevi)
Setting: Secondary
Prior testing: Clinical diagnosis; basis for referral for
US not described
Exclusion criteria: None reported
Sample size (patients): No. eligible: 70
Sample size (lesions): No. included: 70
Participant characteristics: Mean age: NR. Male:
NR.
Lesion characteristics: Melanoma thickness on
histology ranged from 0.25 to 6 mm (n=19)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Ultrasound: High frequency (20MHz); Colour Doppler (7 MHz) 
Test detail: Esaote-Biomedica AU4 Idea (Genoa, Italy). HFUS - 20-MHz annular probe with an axial
resolution of 20 µm and a lateral resolution of 100 µm; Doppler - a 13-MHz linear probe with an axial
resolution of 200 µm and a lateral resolution of 400 µm for performing pulsed and Colour Doppler US.
Theoretical depth explored was 16 mm (HFUS) and 40 mm (linear/Doppler)
Method of diagnosis: In person diagnosis
Prior test data available: Unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: HFUS - Hypoechoic with a homogeneous echostructure and well-defined lower
and lateral margins; HFUS plus Doppler: hypoechoic with a homogeneous echostructure and well-
defined lower and lateral margins OR presence of intratumoral vessels on Doppler
Diagnosis based on: Unclear whether single or multiple observers (n=NR)
Observer qualifications: Not reported
Experience in practice: Not described
Experience with index test: Not described
All tests
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
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B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological diagnosis
alone
Details: None reported
Target condition (Final diagnoses) 
Melanoma (invasive or in situ): 19; BCC: 31; plus
1 neurosarcoma
'Benign' diagnoses: 12 benign nevi, seborrhoeic
keratosis
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Index test to reference standard interval: "After
surgical resection, tumors were analyzed
histologically"
Exclusions: 6/38 clinically suspected MEL not
visualised on HFUS (including 3 melanomas);
plus 1/32 suspected BCC lesions were not
visualised on US and were excluded leaving 63
lesions reported for HFUS
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Rallan 2007
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A. Risk of Bias
Patient Sampling
Study design: Case control (only selected
diagnoses included)
Data collection: Unclear
Period of data collection: NR
Country: UK
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
Inclusion criteria: Patients referred to a skin cancer
clinic with a suspicion of melanoma and with a
subsequent clinical diagnosis of SK, benign nevus,
or suspicion of melanoma
Setting: Specialist clinic
Prior testing: Clinical diagnosis by a dermatologist;
basis for referral for US not described
Exclusion criteria: Head/neck excluded; > 20 mm
excluded
Sample size (patients): No. eligible: 87
Sample size (lesions): No. included: 87
Participant characteristics: Mean age: NR (range 21
to 67y). Male: 24; 28%
Lesion characteristics: Mean Breslow thickness for
invasive melanomas: 0.97+/-0.29 mm, range 0.25
mm to 2.0 mm.
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match
the review question? High
Index Test
Index tests
Ultrasound: High frequency (20MHz) with Reflex Transmission Imaging (RTI)
Test detail: Dermascan Cv3 Cortex ApS (Denmark); three types of images generated - a reflex
transmission image (RTI) predominantly influenced by ultrasonic attenuation in the focal plane, a
‘‘lesional backscatter image’’ (LBI) based on an integration zone through the lesion body and an ‘‘entry
echo image’’ (EEI) based on an integration zone through the skin surface. "RTI parameters refer to
lesion attenuation properties, LBI and EEI parameters depict intralesional sound reflection and surface
sound reflectance characteristics, respectively". Referenced to Rallan 2006, however relatively
experimental in nature.
Method of diagnosis: In person diagnosis
Prior test data available: Unclear whether clinical diagnosis provided to sonographer
Diagnostic threshold: Based on presence of statistically significant characteristics related to contrast
and relative heterogeneity of each type of image (these were identified from comparison of mean
values between MM vs SK and MM vs BN). Three significant characteristics were identified - RTI
contrast, LBI relative heterogeneity, and EEI relative heterogeneity
Diagnosis based on: Unclear whether single or multiple observers (n=NR)
Observer qualifications: Not reported
Experience in practice: Not described
Experience with index test: Not described
All tests
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Type of reference standard: Histological
diagnosis alone
Details: Lesions were "removed under local
anaesthetic following data acquisition.
Histological diagnosis was then used to
classify the lesion in one of three groups, MM,
SK, or other benign-pigmented lesion. In cases
of histological atypia or dyplasia, suggesting
but not confirming melanoma, the lesion was
classed in accordance with the clinical
management protocol (usually as melanoma)."
Target condition (Final diagnoses) 
Melanoma (invasive): 14; Melanoma in situ: 11;
BCC: 0.
'Benign' diagnoses: 38 benign nevi, 24
seborrhoeic keratosis
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Were the reference standard results interpreted without knowledge of the
referral diagnosis? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Index test to reference standard interval:
Consecutive
Exclusions: No lesions reported that were not
visualised on US
Was there an appropriate interval between index test and reference
standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes -
 
Footnotes
Characteristics of excluded studies 
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Reason for exclusion EXCLUDE on index test; Doppler US
 
Bezugly 2015
Reason for exclusion EXCLUDE not a primary study
 
Bobadilla 2008
Reason for exclusion EXCLUDE on study population; only BCC lesions included
 
Cardenas 2009
Reason for exclusion EXCLUDE on index test; 17 MHz frequency
 
Delfino 2013
Reason for exclusion EXCLUDE on index test; 17-MHz ultrasound probe
 
Evans 2014
Reason for exclusion EXCLUDE not a primary study
 
Fornage 1993
Reason for exclusion EXCLUDE on reference standard; Maximum of 41% of benign group had adequate
reference standard (if assume all malignant had histology) From paper - Pathologic
diagnosis obtained for 109 lesions (54%) through shave, punch, or excisional biopsy;
in the absence of pathologic analysis, the diagnosis was based on the dermatologist's
assessment
 
Giovagnorio 2003
Reason for exclusion EXCLUDE on target condition; detection of metastases
 
Gropper 1993
Reason for exclusion EXCLUDE not a primary study; Review
 
Harland 1993
Reason for exclusion EXCLUDE on sample size; 3 BCC; 1 SCC
 
Hernandez 2014
Reason for exclusion EXCLUDE not a primary study; Comment paper
 
Hughes 1987
Reason for exclusion EXCLUDE on target condition
NO breakdown of 17 malignant lesions undergoing Doppler
EXCLUDE on index test
HFUS reported for thickness only; Doppler flow +/- also reported
 
Hunger 2012
Reason for exclusion EXCLUDE on index test; High definition Laser Doppler 
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Jambusaria-Pahlajani 2009
Reason for exclusion EXCLUDE on study population; Only biopsy confirmed BCC or SCC
EXCLUDE on target condition; Detection of surgical margin
 
Karaman 2001
Reason for exclusion EXCLUDE on index test; Power Doppler
 
Krahn 1998
Reason for exclusion EXCLUDE on target condition; Exclude HF ultrasound data - only reports accurate
detection of lesion thickness; include for VI/Dermoscopy
 
Maj 2015
Reason for exclusion EXCLUDE on 2x2 data; Paper refers to Table I which contains 'detailed data' but there
is no Table I in the paper
EXCLUDE but contact authors; contacted Dec 2016 and May 2017
 
Marques 2002
Reason for exclusion EXCLUDE on index test; 10 Mhz ultrasound - not high frequency
 
Meyer 2014
Reason for exclusion EXCLUDE on target condition; identification of lesion thickness only
 
Ozkol 2006
Reason for exclusion EXCLUDE on target condition; D+ group includes 1 dermatofibroma and 1 Bowen's;
cannot disaggregate
EXCLUDE on index test; Colour Doppler
 
Petik 2013
Reason for exclusion EXCLUDE on index test; Colour Doppler plus Power Doppler if vascularity not clearly
identified
 
Rallan 2006
Reason for exclusion EXCLUDE if derivation study; High-resolution ultrasound with reflex transmission
imaging (RTI); also combined with white light clinical (WLC) photography. No separate
independent test set result is given; also 'white light' data is CAD based
 
Ravi 2000
Reason for exclusion EXCLUDE on index test; Colour Doppler
 
Samimi 2010
Reason for exclusion EXCLUDE on study population; Blue naevus or melanoma mets
EXCLUDE on target condition; Melanoma metastasis
 
Schroder 1999
Reason for exclusion EXCLUDE on index test; Not high frequency (10 MHz US)
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Schröder 2001
Reason for exclusion EXCLUDE on index test; Not HFUS
 
Scotto 2015
Reason for exclusion EXCLUDE on index test; US (5-17MHz) and Doppler
 
Song 2014
Reason for exclusion EXCLUDE on index test; Not high frequency US (7-15MHz)
 
Srivastava 1986
Reason for exclusion EXCLUDE on index test; Doppler US
 
Stucker 2002
Reason for exclusion EXCLUDE on index test; Laser Doppler; assessment of blood flow
 
Stücker 1999
Reason for exclusion EXCLUDE on index test; laser Doppler US
EXCLUDE on 2x2 data; comparing mean tumour perfusion values between groups
only
 
Wortsman 2010
Reason for exclusion EXCLUDE on target condition; Can estimate sensitivity for detection of malignancy but
cannot estimate specificity for benign lesions assessed to either rule in or rule out
malignancy
EXCLUDE on index test; Up to 15MHz ultrasound
EXCLUDE on 2x2 data; could get 2x2 from Table 1 but disease negative includes
huge range of diagnoses that are not relevant to our review
 
Wortsman 2013
Reason for exclusion EXCLUDE not a primary study
 
Footnotes
Characteristics of studies awaiting classification 
Bens 2015
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Patient Sampling -
 
Patient characteristics and setting -
 
Index tests -
 
Target condition and reference
standard(s)
-
 
Flow and timing -
 
Comparative -
 
Notes British Library unable to supply copy of the paper; author contacted
 
Nitsche 1992
Patient Sampling -
 
Patient characteristics and setting -
 
Index tests -
 
Target condition and reference
standard(s)
-
 
Flow and timing -
 
Comparative -
 
Notes British Library unable to supply copy of the paper
 
Footnotes
Characteristics of ongoing studies 
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Question What is the diagnostic accuracy of high frequency ultrasound (HFUS) for the diagnosis of cutaneousmelanoma or BCC in adults?
Participants Adults with suspicious skin lesions.
Prior testing
and
prevalence
Studies varied in, or did not report, the basis for participant referral for ultrasound. One implied that half of
included lesions were difficult to diagnose and two included only three lesion types. Prevalence of melanoma
ranged from 14% to 58% (median 30%) and BCC from 8% to 49% (median 17%).
Settings Secondary care and specialist lesion clinics.
Target
condition(s)
Invasive melanoma and melanocytic intraepidermal variants; basal cell carcinoma
Index test High frequency ultrasound (> 20 MHz) alone and in combination with Doppler ultrasound. Lesions notvisualised on ultrasound were excluded by some studies.
Reference
standard
Histology
Action: If accurate, positive results of HFUS will help to appropriately select lesions for excision
Limitations  
Risk of bias:
Patient selection methods unclear or at high risk of bias due to selective inclusion of lesion types. Test
interpretation was blinded to reference standard, but test thresholds were clearly prespecified in only one
study and were data driven (2/6) or not pre-specified (3/6) in the remainder. Reference standard blinding was
not described. Timing of index and reference standards was not reported. Exclusions due to test failures were
not reported (3/6).
Applicability
of evidence to
question:
High (4) or unclear (1) concerns about applicability due to unrepresentative participant samples with high
disease prevalence. Test observers were not described (6/6) and prototype or relatively novel devices used
(2/6). Reference standard interpretation by experienced histopathologists was not described (5/6). Half of
studies were not designed to investigate test accuracy.
Total number
of studies: 6 Total participants with test results 1263 Total number melanoma or BCC 349
Detection of melanoma
Number of
studies 5 Total participants with test results 1125 Total with melanoma 242
Findings
No pooled analysis was conducted due to between study heterogeneity and small study numbers. Derived
sensitivities for investigated HFUS characteristics were at least 83% (95% CI 75% to 90%); the combination
of three qualitative features (lesions appearing hypoechoic, homogenous and well defined) demonstrating
100% sensitivity in two studies, with variable specificities of 33% (95% CI 20% to 48%) and 73% (95% CI
57% to 85%). Quantitative measurement of HFUS outputs in two studies enabled decision thresholds to be
set to achieve 100% sensitivity; resulting specificities were 93% (95% CI 77% to 99%) and 65% (95% CI 51%
to 76%). Between 7 and 38 lesions were not visualised on HFUS (reported in 3 studies); including between 3
and 5 melanomas not visualised (in each of the 3 studies).
Detection of BCC
Number of
studies 3 Total participants with test results 993 Total with BCC 119
Findings Only qualitative thresholds were assessed; sensitivities and specificities were highly variable, makingsummary statements difficult.
Footnotes
HFUS - high frequency ultrasound; BCC - basal cell carcinoma; CI - confidence interval.
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Test StudiesParticipants
1 Melanoma - hypoechoic 1 792
2 Melanoma - hypoechoic and homogenous 1 792
3 Melanoma - hypoechoic and sharp basal margins 1 792
4 Melanoma - hypoechoic and sharp lateral margins 1 792
5 Melanoma - hypoechoic, homogenous and well defined 2 177
6 Melanoma (MM vs BN) - hypoechoic, homogenous and well defined 1 32
7 Melanoma (MM vs SK) - DER<3 1 54
8 Melanoma (MM vs SK) - absence of EEL 1 54
9 Melanoma (MM vs SK) - DER<3 OR absence of EEL 1 54
10 Melanoma (MM vs SK/BN) - absence of EEL 1 69
11 Melanoma - RTI contrast/LBI rel. heterogeneity/EEI rel. heterogeneity1 87
12 Melanoma - HFUS+ve OR Doppler +ve 1 63
13 Melanoma (MM vs BN) - HFUS+ve OR Doppler +ve 1 32
14 Melanoma - HFUS+ve AND Doppler +ve 2 170
15 BCC - hypoechoic 2 930
16 BCC - hypoechoic and homogenous 2 930
17 BCC - hypoechoic and well defined 1 138
18 BCC - hypoechoic and sharp basal margins 1 792
19 BCC - hypoechoic and sharp lateral margins 1 792
20 BCC - hypoechoic, homogenous and well defined 1 63
21 BCC - hypoechoic, heterogenous with irregular margins 1 63
22 BCC - HFUS+ve AND Doppler +ve 1 138
Figures
Figure 1
Caption
Sample photographs of superficial spreading melanoma (left), BCC (centre), and cSCC (right)
Figure 2
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Caption
The principles of B-mode ultrasound echographic imaging of the skin
Figure 3
#164c High frequency ultrasound for the diagnosis of skin cancer in adults
50 / 87
Caption
Modern laptop based DermaScan C® (2D) (Copyright © 2018 Cortex Technology ApS: reproduced with permission)
Figure 4
Caption
Illustrates the well defined margins, low level and homogenous internal echoes, lack of strong entry echo and lack of acoustic
shadowing for melanoma (c. and d.) and contrasting image for BCC (a. and b.) (from Harland 2001, Copyright © 2018 John
Wiley and Sons, reproduced with permission)
Figure 5
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Caption
Current clinical pathway for people with skin lesions
Figure 6
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Caption
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PRISMA flow diagram.
Figure 7
Caption
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 8
Caption
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 9 (Analysis 1) 
#164c High frequency ultrasound for the diagnosis of skin cancer in adults
54 / 87
Caption
Forest plot of tests for differentiation of melanoma from other lesions using combinations of HFUS characteristics and
quantitative measurements of HFUS outputs
Figure 10 (Analysis 2) 
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Caption
Forest plot of tests for the differentiation of melanoma from other lesions using HFUS and Doppler US
Figure 11 (Analysis 3) 
Caption
Forest plot of tests for the differentiation of BCC from other lesion types using HFUS
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List of reviews  
Estimated number of
studies Diagnosis of melanoma 
1. Visual inspection versus visual inspection plus dermoscopy 120
2. Teledermatology 12
3. Mobile phone applications 2
4. Computer-aided diagnosis: dermoscopy based and spectroscopy based techniques 37
5. Reflectance confocal microscopy 19
6. High frequency ultrasound 3
7. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Diagnosis of keratinocyte skin cancer (basal cell carcinoma and cutaneous squamous cell
carcinoma)
 
8. Visual inspection ± dermoscopy 22
9. Computer aided diagnosis: dermoscopy based and spectroscopy based techniques 3
10. Optical coherence tomography 6
11. Reflectance confocal microscopy 9
12. High frequency ultrasound 1
13. Exfoliative cytology 5
14. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of melanoma  
15. Ultrasound 25 to 30
16. Computer tomography 5 to 10
17. Positron emission tomography or positron emission tomography-computer tomography 20 to 25
18. Magnetic resonance imaging 5
19. Sentinel lymph node biopsy ± high frequency ultrasound 70
20. Overview: comparing the accuracy of tests for which sufficient evidence was identified either
alone or in combination –
Staging of cutaneous squamous cell carcinoma  
21. Imaging tests review 10 to 15
22. Sentinel lymph node biopsy ± high frequency ultrasound 15 to 20
2 Glossary of terms
Term Definition
Atypical intraepidermal
melanocytic variant
Unusual area of darker pigmentation contained within the epidermis that may progress to an
invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the skin
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the control of
cell growth. BRAF mutations (damaged DNA) occur in around 40% of melanomas, which
can then be treated with particular drugs.
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF mutated
metastatic melanoma.
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a microscope,
measured in mm from the top layer of skin to the bottom of the tumour.
Congenital naevi A type of mole found on infants at birth
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Term Definition
 
Dermoscopy
Whereby a handheld microscope is used to allow more detailed, magnified, examination of
the skin compared to examination by the naked eye alone
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies them
as disease-free.
False positive An individual who is truly disease-free, but whom a diagnostic test classifies them as having
the disease.
Histopathology/Histology The study of tissue, usually obtained by biopsy or excision, for example under a microscope.
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which includes
malignant cells but with no invasive growth. May progress to an invasive melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that travels
around the body to help fight disease; they are located throughout the body often in clusters
(nodal basins).
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as ‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual studies.
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the bloodstream or
the lymphatic system.
Micrometastases Micrometastases are metastases so small that they can only be seen under a microscope.
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour.
Morbidity Detrimental effects on health.
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which reflects the
number of deaths per unit of population in relation to any specific region, age group,
disease, treatment or other classification, usually expressed as deaths per 100, 1000,
10,000 or 100,000 people.
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g. urology,
oncology, pathology, radiology, and nursing). Cancer care in the National Health Service
(NHS) uses this system to ensure that all relevant health professionals are engaged to
discuss the best possible care for that patient.
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the patient’s
prognosis.
Receiver operating
characteristic (ROC) plot
A plot of the sensitivity and 1 minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a range of
binary test results
Receiver operating
characteristic (ROC) analysis
The analysis of a ROC plot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can occur either
at the site of the original tumour or at other sites in the body.
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of a patient in an
evaluation of a diagnostic test
Reflectance confocal
microscopy (RCM)
A microscopic technique using infrared light (either in a handheld device or a static unit) that
can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of individuals with a disease who
have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with benign skin
lesions) who have that absence of disease correctly identified by the study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into internationally
agreed categories.
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Term Definition
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or physical
examination.
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer cells
throughout the body rather than targeting one specific area.
3 Table of acronyms and abbreviations used
Acronym Definition
μm micrometre
AHM amelanotic or hypomelanotic melanoma
AK actinic keratosis
AMN atypical melanocytic naevi
AUC area under the curve
B-mode brightness mode
BCC basal cell carcinoma
BD Bowen’s disease
BN benign naevi
BNM benign non-melanocytic
BPC between person comparison (of tests)
CAD computer assisted diagnosis
CCS case control study
CD compact disc
CM cutaneous melanoma
CMM cutaneous malignant melanoma
CS case series
CSCC cutaneous squamous cell carcinoma
D- disease negative
D+ disease positive
DER dermal echogenicity ratio
DF dermatofibroma
Dx diagnosis
EEI entry echo image
EEL entry echo line
ELM epiluminescence microscopy
FN false negative
FP false positive
FU Follow- up
GP general practitioner
H&E haematoxylin and eosin stain
HFUS high frequency ultrasound
Hz hertz
KHz kilohertz
LBI lesional backscatter image
LPLK lichen planus- like keratosis
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Acronym Definition
LS lentigo simplex
MEL melanoma (invasive or in situ)
MHz megahertz
MiS melanoma in situ (or lentigo maligna)
MM malignant melanoma
mm millimetre
MN melanocytic naevi
MSDSLA multispectral digital skin lesion analysis device
n number
N/A not applicable
NC non comparative
NMLs non melanocytic lesions
No. number
NPV negative predictive value
NR not reported
P prospective
PCPs primary care providers
PLC pigmented lesion clinic
PPV positive predictive value
PRF pulse-repetition frequency
PSL pigmented skin lesion
R retrospective
RCM reflectance confocal microscopy
RCT randomised controlled trial
RTI reflex transmission image
SCC squamous cell carcinoma
SD standard deviation
SDDI Short-term sequential digital dermoscopy imaging
se sensitivity
sp specificity
SK seborrhoeic keratosis
SN Spitz nevi
SSM superficial spreading melanoma
TD teledermatology
TN true negative
US ultrasound
VI visual inspection
WPC within person comparison (of tests)
WPC-algswithin person comparison (of algorithms)
4 Proposed sources of heterogeneity
i. Population characteristics
general versus higher risk populations
patient population: Primary /secondary / specialist unit
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lesion suspicion: general suspicion/atypical/equivocal/NR
lesion type: any pigmented; melanocytic
inclusion of multiple lesions per participant
ethnicity
ii. Index test characteristics
the nature of and definition of criteria for test positivity
observer experience with the index test
approaches to lesion preparation (e.g. the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
reference standard used
whether histology-reporting meets pathology-reporting guidelines
use of excisional versus diagnostic biopsy
whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
consecutive or random sample of participants recruited
index test interpreted blinded to the reference standard result
index test interpreted blinded to the result of any other index test
presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by
the reference test or by the same reference test with selection dependent on the index test result)
use of an adequate reference standard
overall risk of bias
5 Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
#164c High frequency ultrasound for the diagnosis of skin cancer in adults
61 / 87
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
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71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 "Sensitivity and Specificity"/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
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1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or
adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1
or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
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45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$ or tele-dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
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91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$
or epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or
keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
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34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or
teledermatoscop$).mp. or tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
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80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 "Sensitivity and Specificity"/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
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Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 "skin cancer*"
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#6 nmsc
#7 "squamous cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 "basal cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 "visual inspect*"
#20 "visual exam*"
#21 (clinical or physical) next (exam*)
#22 "3 point"
#23 "three point"
#24 "pattern analys*"
#25 ABDC
#26 menzies
#27 "7 point"
#28 "seven point"
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 "artificial intelligence"
#31 "AI"
#32 "computer assisted"
#33 "computer aided"
#34 AI
#35 "neural network*"
#36 MoleMax
#37 "computer diagnosis"
#38 "image process*"
#39 "automatic classif*"
#40 SIAscope
#41 "image analysis"
#42 "optical near/2 scan*"
#43 Aura
#44 MelaFind
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#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 "confocal microscopy"
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 "mitotic index"
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 "Mole Detective"
#60 "Spot Check"
#61 mole* near/2 map*
#62 total near/2 body
#63 "exfoliative cytolog*"
#64 "digital analys*"
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatolog*
#67 "optical coherence" next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or
#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45
or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or
#63 or #64 or #65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 "CAT SCAN" or "CATSCAN"
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 "magnetic resonance imag*"
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 "positron emission tomograph*"
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or "false negative*" or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
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#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 "electrical impedance spectroscopy"
#100 "history taking"
#101 "patient history"
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 "ugly duckling" or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 "clinical accuracy"
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 "diagnostic algorithm*"
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 "virtual image*"
#115 "volatile organic compound*"
#116 dog or dogs
#117 VOC
#118 "gene expression analys*"
#119 "reflex transmission imaging"
#120 "thermal imaging"
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111
or #112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database: CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH "Melanoma") OR (MH "Nevi and Melanomas+")
S2 (MH "Skin Neoplasms+")
S3 (MH "Carcinoma, Basal Cell+")
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or
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epithelioma* or lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH "Keratinocytes")
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or
(seven point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or
DermoScan or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH "Diagnosis, Computer Assisted+")
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop*
or tele-dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH "Sentinel Lymph Node Biopsy")
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 "Patient history"
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
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S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR
S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR
S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH "Deoxyglucose+")
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH "Deoxyglucose+")
S72 (MH "Tomography, Emission-Computed+")
S73 (MH "Tomography, X-Ray Computed")
S74 positron emission tomograph*
S75 (MH "Magnetic Resonance Imaging+")
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77
OR S78 OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH "Neoplasm Staging")
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
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#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or
epithelioma* or lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or "incident light" or "surface
microscop*" or "visual inspect*" or "physical exam*" or 3 point or three point or pattern analy* or ABCDE or menzies or 7
point or seven point or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural
network* or Molemax or image process* or automatic classif* or image analysis or siascope or optical scan* or Aura or
melafind or simsys or molemate or solarscan or vivascope or confocal microscop* or high ultraso* or canine detect* or
cellphone* or mobile* or phone* or smartphone or dermoscan or skinvision or dermlink or spotcheck or spot check or mole
detective or mole map* or total body or exfoliative psychology or digital or image software or optical coherence or
teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos* or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or
physical exam* or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general
practice or confocal microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile
organic or VOC or dog* or gene expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron
emission or computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or
sonograph* or ultraso* or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
6 Full text inclusion criteria
Criterion Inclusion Exclusion
 
Study design
 
For diagnostic and staging reviews
Any study for which a 2×2 contingency table can be
extracted, e.g.
diagnostic case control studies
'cross-sectional' test accuracy study with
retrospective or prospective data collection
studies where estimation of test accuracy was not the
primary objective but test results for both index and
reference standard were available
RCTs of tests or testing strategies where participants
were randomised between index tests and all
undergo a reference standard (i.e. accuracy RCTs)
 
< 5 melanoma cases (diagnosis reviews)
< 10 participants (staging reviews)
Studies developing new criteria for diagnosis
unless a separate 'test set' of images were
used to evaluate the criteria (mainly digital
dermoscopy)
Studies using 'normal' skin as controls
Letters, editorials, comment papers, narrative
reviews
Insufficient data to construct a 2×2 table
Target
condition
 
Melanoma
Keratinocyte skin cancer (or non-melanoma skin
cancer)
BCC or epithelioma
cSCC
 
Studies exclusively conducted in children
Studies of non-cutaneous melanoma or SCC
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Criterion Inclusion Exclusion
Population For diagnostic reviews
Adults with a skin lesion suspicious for melanoma, BCC,
or cSCC (other terms include pigmented skin
lesion/nevi, melanocytic, keratinocyte, etc.)
Adults at high risk of developing melanoma skin cancer,
BCC, or cSCC
For staging reviews
Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or distant
metastases or both
 
People suspected of other forms of skin cancer
Studies conducted exclusively in children
Index tests For diagnosis
Visual inspection/clinical examination
Dermoscopy/dermatoscopy
Teledermoscpoy
Smartphone/mobile phone applications
Digital dermoscopy/artificial intelligence
Confocal microscopy
Ocular coherence tomography
Exfoliative cytology
High frequency ultrasound
Canine odour detection
DNA expression analysis/gene chip analysis
Other
For staging
CT
PET
PET-CT
MRI
Ultrasound +/fine needle aspiration cytology FNAC
SLNB +/high frequency ultrasound
Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope used)
 
Sentinel lymph biopsy for therapeutic rather
than staging purposes
Tests to determine melanoma thickness
Tests to determine surgical margins/lesion
borders
Tests to improve histopathology diagnose
LND
Reference
standard
 
For diagnostic studies
Histopathology of the excised lesion
Clinical follow-up of non-excised/benign appearing
lesions with later histopathology if suspicious
Expert diagnosis (studies should not be included if
expert diagnosis is the sole reference standard)
For studies of imaging tests for staging
Histopathology (via LND or SLMB)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging
LND of both SLN+ and SLn participants to identify all
diseased nodes
LND of SLN+ participants and follow-up of SLN
participants to identify a subsequent nodal recurrence in
a previously investigated nodal basin
 
For diagnostic studies
Exclude if any disease positive participants
have diagnosis unconfirmed by histology
Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
Exclude studies of referral accuracy, i.e.
comparing referral decision with expert
diagnosis, unless evaluations of
teledermatology or mobile phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle
aspiration cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography;
PET-CT: positron emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell
carcinoma; SLN+: positive sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy.
7 Quality assessment (based on QUADAS-2)
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The QUADAS-2 checklist (Whiting 2011) was tailored to the review topic as follows below.
Patient selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible
to undergo a test should be included in a study, allowing for the intended use of that test within the context of the study. We
considered studies that separately sampled malignant and benign lesions to have used a case-control design; and those that
supplemented a series of suspicious lesions with additional malignant or benign lesions to be at unclear risk of bias
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion
sites, or that excluded lesions on the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at
high risk of bias.
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion
populations, such as melanocytic, nodular, high risk or restrictions by size to be of high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions
to contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We
considered studies that include a high number of lesions in relation to the number of study to be less representative than
studies conducted in a more general population participants (i.e. if the difference between the number of included lesions and
number of included participants is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to
the result of the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that
used the original index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the
reference standard is known; however, studies using previously acquired images could be particularly susceptible to
information bias. For these studies to be at low risk of bias, we required a clear indication that observers were unaware of the
reference standard diagnosis at time of test interpretation. An item was also added to assess the presence of blinding
between interpretations of different algorithms, however this item was not included in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was
not data driven, i.e. was not based on study results. Studies that did not clearly describe the threshold used but that required
clinicians to record a diagnosis or management decision for a lesion were considered to be unclear on this criterion. Studies
reporting accuracy for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported
accuracy for the presence of independently significant lesion characteristics with no separate test set of lesions were
considered at high risk of bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would
be in a clinical practice setting, i.e. in-person or face-to-face with the patient, and by a single observer as opposed to a
consensus decision or average across multiple observers. Image-based studies were considered to be high concern,
although for some tests (e.g. RCM) image interpretations where the observer was also supplied with a clinical or
dermoscopic image of the lesion along with some patient characteristics were considered ‘unclear’.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion
characteristics that were considered to be indicative for melanoma, particularly where established algorithms or checklists
were not used. Studies were considered of low concern if the threshold used was established in a prior study or sufficient
threshold details were presented to allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test
interpreter as ‘experienced’ or ‘expert’ to have low concern about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion
regardless of level of clinical suspicion of melanoma. In reality, both partial and differential verification bias are likely. Partial
verification bias may occur where histology is the only reference standard used, and only those participants with a certain
degree of suspicion of malignancy based on the result of the index test undergo verification, the others either being excluded
from the study or defined as being disease-negative without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of
suspicious lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with
benign-appearing lesions but instead follow them up for a period of time to determine whether any malignancy subsequently
develops (these would be false-negatives on the index test). We defined an 'adequate' reference standard as: all disease-
positive individuals having a histological reference standard either at the time of application of the index test or after a period
of clinical follow-up; and at least 80% of disease-negative participants have received a histological diagnosis, with up to 20%
undergoing at least three months' follow-up of benign-appearing lesions.
A further challenge is the potential for incorporation bias, i.e. where the result of the index test is used to help determine the
reference standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to
be included on pathology request forms and for the histopathologist to use this diagnosis to help with the pathology
interpretation. Although inclusion of such clinical information on the histopathology request form is theoretically a form of
incorporation bias, blinded interpretation of the histopathology reference standard is not normal practice, and enforcement of
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such conditions would significantly limit the generalisability of the study results. For studies evaluating tests other than visual
inspection or dermoscopy, this item was divided into two questions, firstly whether the reference standard was blinded to the
index test result, and secondly whether it was blinded to the clinical diagnosis. Only the response to the first part (i.e. blinding
to index test) was included in our overall assessment of risk of bias for the reference standard domain.
In judging the applicability of the reference standard to our review question, scored studies as high concern around
applicability if they used expert diagnosis (with no follow-up) as a reference standard in any patient, or did not report
histology interpretation by a dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or
as near to each other in time as possible to avoid changes in lesion over time. For lesions with a histological
reference standard, we have defined a one-month period as an appropriate interval between application of the index
test and the reference standard. For studies using clinical follow-up, a minimum three-month follow-up period has
been defined as at low risk of bias for detecting false-negatives. This interval was chosen based on a study showing
that most false-negative melanomas will be diagnosed within three months of the initial negative index test although
a small number will be diagnosed up to 12 months subsequently (Altamura 2008).
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were
excluded following recruitment.
Comparative domain
A comparative domain was added to the QUADAS-2 checklist for studies comparing the accuracy of RCM and dermoscopy.
Items were included to assess the presence blinding of interpretation between tests, and to specify a maximum of one month
interval between application of index tests, as intervals greater than these may be accompanied by changes in tumour
characteristics. As it would not be normal practice for RCM to be interpreted blinded to the clinical or dermoscopic diagnosis,
the scoring of this item did not contribute to our overall assessment of risk of bias. We also considered whether both tests
were applied and interpreted in a clinically applicable manner.
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues ( Whiting 2011 ).
Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
1) Was a consecutive or random sample of participants or
images enrolled?
Yes – if paper states consecutive or random
No – if paper describes other method of sampling
Unclear – if participant sampling not described
2) Was a case-control design avoided? Yes – if consecutive or random or case-control design
clearly not used
No – if study described as case-control or describes
sampling specific numbers of participants with particular
diagnoses
Unclear – if not described
 
3) Did the study avoid inappropriate exclusions, e.g.
'difficult to diagnose' lesions not excluded
lesions not excluded on basis of disagreement between
evaluators
Yes - if inappropriate exclusions were avoided
No – if lesions were excluded that might affect test
accuracy, e.g. 'difficult to diagnose' lesions, or where
disagreement between evaluators was observed
Unclear – if not clearly reported but there is suspicion that
difficult to diagnose lesions may have been excluded
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
4) For between-person comparative studies only (i.e. allocating
different tests to different study participants):
A) were the same participant selection criteria used for those
allocated to each test?
B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised
sequence?
C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to
assignment?
For A)
Yes – if same selection criteria were used for each index
test, No – if different selection criteria were used for each
index test, Unclear – if selection criteria per test were not
described, N/A – if only 1 index test was evaluated or all
participants received all tests
For B)
Yes – if adequate randomisation procedures are
described, No – if inadequate randomisation procedures
are described, Unclear – if the method of allocation to
groups is not described (a description of 'random' or
'randomised' is insufficient), N/A – if only 1 index test
was evaluated or all participants received all tests
For C)
Yes – if appropriate methods of allocation concealment
are described, No – if appropriate methods of allocation
concealment are not described, Unclear – if the method
of allocation concealment is not described (sufficient
detail to allow a definite judgement is required), N/A – if
only 1 index test was evaluated
 
Could the selection of participants have introduced bias?
For non-comparative and within person-comparative studies
If answers to all of questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For between-person comparative studies
If answers to all of questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
 
For non-comparative and within person-comparative
studies
Risk is low1.
Risk is high2.
Risk unclear3.
For between-person comparative studies
Risk is low1.
Risk is high2.
Risk unclear3.
PARTICIPANT SELECTION (1) - CONCERNS REGARDING APPLICABILITY
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
1) Are the included participants and chosen study setting
appropriate to answer the review question, i.e. are the study
results generalisable?
This item is not asking whether exclusion of certain
participant groups might bias the study's results (as in Risk
of Bias above), but is asking whether the chosen study
participants and setting are appropriate to answer our review
question. Because we are looking to establish test accuracy
in both primary presentation and referred participants, a
study could be appropriate for 1 setting and not for the other,
or it could be unclear as to whether the study can
appropriately answer either question
For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a
skin lesion or B) referred participants, and respond to the
questions in either A) or B) accordingly. If the study gives
insufficient details, please respond Unclear to both parts of
the question
 
A) For studies that will contribute to the analysis of
participants with a primary presentation of a skin lesion (i.e.
test naive)
Yes – if participants included in the study appear to be
generally representative of those who might present in a
usual practice setting
No – if study participants appear to be unrepresentative of
usual practice, e.g. in terms of severity of disease,
demographic features, presence of differential diagnosis or
comorbidity, setting of the study, and previous testing
protocols
Unclear – if insufficient details are provided to determine
the generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e. who have already undergone some form of
testing)
Yes – if study participants appear to be representative of
those who might be referred for further investigation. If the
study focuses only on those with equivocal lesions, for
example, we would suggest that this is not representative of
the wider referred population
No – if study participants appear to be unrepresentative of
usual practice, e.g. if a particularly high proportion of
participants have been self-referred or referred for cosmetic
reasons. Other factors to consider include severity of
disease, demographic features, presence of differential
diagnosis or comorbidity, setting of the study, and previous
testing protocols
Unclear – if insufficient details are provided to determine
the generalisability of study participants
2) Did the study avoid including participants with multiple
lesions?
Yes – if the difference between the number of included
lesions and number of included participants is less than 5%
No – if the difference between the number of included
lesions and number of included participants is greater than
5%
Unclear – if it is not possible to assess
 
Is there concern that the included participants do not match the
review question?
If the answer to question 1) or 2) 'Yes':1.
If the answer to question 1) or 2) 'No':2.
If the answer to question 1) or 2) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
INDEX TEST (2) - RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted
without knowledge of the results of the reference standard?
Yes – if index test described as interpreted without
knowledge of reference standard result or, for prospective
studies, if index test is always conducted and interpreted
prior to the reference standard
No – if index test described as interpreted in knowledge of
reference standard result
Unclear – if index test blinding is not described
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
2) Was the diagnostic threshold at which the test was
considered positive (i.e. melanoma present) prespecified?
Yes – if threshold was prespecified (i.e. prior to analysing
study results)
No – if threshold was not prespecified
Unclear – if not possible to tell whether or not diagnostic
threshold was prespecified
3) For within-person comparisons of index tests or testing
strategies (i.e. > 1 index test applied per participant): was each
index test result interpreted without knowledge of the results of
other index tests or testing strategies?
Yes – if all index tests were described as interpreted
without knowledge of the results of the others
No – if the index tests were described as interpreted in the
knowledge of the results of the others
Unclear – if it is not possible to tell whether knowledge of
other index tests could have influenced test interpretation
N/A – if only 1 index test was evaluated
 
Could the conduct or interpretation of the index test have
introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1) and 2) 'Yes':1.
If answers to either questions 1) or 2) 'No':2.
If answers to either questions 1) or 2) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), for any index test and 3)1.
'Yes':
If answers to any 1 of questions 1) or 2) for any index test or2.
3) 'No':
If answers to any 1 of questions 1) or 2) for any index test or3.
3) 'Unclear':
 
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
INDEX TEST (2) - CONCERN ABOUT APPLICABILITY
 
1) Was the diagnostic threshold to determine presence or
absence of disease established in a previously published
study?
E.g. previously evaluated/established
algorithm/checklist used
lesion characteristics indicative of melanoma used
objective (usually numerical) threshold used
Yes – if a previously evaluated/established tool to aid
diagnosis of melanoma was used or if the diagnostic
threshold used was established in a previously published
study
No – if an unfamiliar/new tool to aid diagnosis of melanoma
was used, if no particular algorithm was used, or if the
objective threshold reported was chosen based on results
in the current study
Unclear – if insufficient information was reported
 
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold
is described in sufficient detail. This item applies equally to
studies using pattern recognition and those using checklists or
algorithms to aid test interpretation
Yes – If the criteria for diagnosis of melanoma were
reported in sufficient detail to allow replication
No – if the criteria for diagnosis of melanoma were not
reported in sufficient detail to allow replication
Unclear – If some but not sufficient information on criteria
for diagnosis to allow replication were provided
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
3) Was the test interpretation carried out by an experienced
examiner?
Yes – if the test was interpreted by 1 or more speciality-
accredited dermatologists, or by examiners of any clinical
background with special interest in dermatology and with
any formal training in the use of the test
No – if the test was not interpreted by an experienced
examiner (see above)
Unclear – if the experience of the examiner(s) was not
reported in sufficient detail to judge or if examiners were
described as 'Expert' with no further detail given
N/A – if system-based diagnosis, i.e. no observer
interpretation
 
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to questions 1), 2), or 3) 'No':2.
If answers to questions 1), 2), or 3) 'Unclear':3.
 
Concern is low1.
Concern is high2.
Concern is unclear3.
REFERENCE STANDARD (3) - RISK OF BIAS
 
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive – 1 or more of the following:
histological confirmation of melanoma following biopsy or
lesion excision
clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to
a histological diagnosis of melanoma
B) Disease-negative – 1 or more of the following:
histological confirmation of absence of melanoma following
biopsy or lesion excision in at least 80% of disease-negative
participants
clinical follow-up of benign-appearing lesions for a minimum
of 3 months following the index test in up to 20% of disease-
negative participants
 
A) Disease-positive
Yes – if all participants with a final diagnosis of melanoma
underwent 1 of the listed reference standards
No – If a final diagnosis of melanoma for any participant
was reached without histopathology
Unclear – if the method of final diagnosis was not reported
for any participant with a final diagnosis of melanoma or if
the length of clinical follow-up used was not clear or if a
clinical follow-up reference standard was reported in
combination with a participant-based analysis and it was
not possible to determine whether the detection of a
malignant lesion during follow-up is the same lesion that
originally tested negative on the index test
B) Disease-negative
Yes – If at least 80% of benign diagnoses were reached by
histology and up to 20% were reached by clinical follow-up
for a minimum of 3 months following the index test
No – if more than 20% of benign diagnoses were reached
by clinical follow-up for a minimum of 3 months following
the index test or if clinical follow-up period was less than 3
months
Unclear – if the method of final diagnosis was not reported
for any participant with benign or non-melanoma diagnosis
 
2) Were the reference standard results interpreted without
knowledge of the results of the index test?
Please score this item for all studies even though
histopathology interpretation is usually conducted with
knowledge of the clinical diagnosis (from visual inspection or
dermoscopy or both). We will deal with this by not including the
response to this item in the 'Risk of bias' assessment for these
tests. For reviews of all other tests, this item will be retained
Yes – if the reference standard diagnosis was reached
blinded to the index test result
No – if the reference standard diagnosis was reached with
knowledge of the index test result
Unclear – if blinded reference test interpretation was not
clearly reported
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
If answer to question 1) 'Yes':1.
If answer to question 1) 'No':2.
If answer to question 1) 'Unclear':3.
For all other tests
If answers to questions 1) and 2) 'Yes':1.
If answers to questions 1) or 2) 'No':2.
If answers to questions 1) or 2) 'Unclear':3.
 
For visual inspection/dermoscopy evaluations
Risk is low1.
Risk is high2.
Risk is unclear3.
For all other tests
Risk is low1.
Risk is high2.
Risk is unclear3.
REFERENCE STANDARD (3) - CONCERN ABOUT APPLICABILITY
1) Are index test results presented separately for each
component of the target condition (i.e. separate results
presented for those with invasive melanoma, melanoma in situ,
lentigo maligna, severe dysplasia, BCC, and cSCC)?
Yes – if index test results for each component of the target
condition can be disaggregated
No – if index test results for the different components of the
target condition cannot be disaggregated
Unclear – if not clearly reported
 
2) Expert opinion (with no histological confirmation) was not
used as a reference standard
'Expert opinion' means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
***do not complete this item for teledermatology studies
Yes – if expert opinion was not used as a reference
standard for any participant
No – if expert opinion was used as a reference standard for
any participant
Unclear – if not clearly reported
3) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes – if histology interpretation was reported to be carried
out by an experienced histopathologist or
dermatopathologist
No – if histology interpretation was reported to be carried
out by a less experienced histopathologist
Unclear – if the experience/qualifications of the pathologist
were not reported
 
Is there concern that the target condition as defined by the
reference standard does not match the review question?
If answers to all questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
***For teledermatology studies only
If answers to all questions 1) and 3) 'Yes':1.
If answers to questions 1) or 3) 'No':2.
If answers to questions 1) or 3) 'Unclear':3.
Concern is low1.
Concern is high2.
Concern is unclear3.
***For teledermatology studies only
Concern is low1.
Concern is high2.
Concern is unclear3.
FLOW AND TIMING (4): RISK OF BIAS
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Item Response (delete as required)
PARTICIPANT SELECTION (1) - RISK OF BIAS
 
1) Was there an appropriate interval between index test and
reference standard?
A) For histopathological reference standard, was the interval
between index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of
borderline/benign-appearing lesions, was there at least 3
months' follow-up following application of index test(s)?
 
A)
Yes – if study reports ≤ 1 month between index and
reference standard
No – if study reports > 1 month between index and
reference standard
Unclear – if study does not report interval between index
and reference standard
B)
Yes – if study reports ≥ 3 months' follow-up
No – if study reports < 3 months' follow-up
Unclear – if study does not report the length of clinical
follow-up
2) Did all participants receive the same reference standard? Yes – if all participants underwent the same reference
standard
No – if more than 1 reference standard was used
Unclear – if not clearly reported
3) Were all participants included in the analysis? Yes – if all participants were included in the analysis
No – if some participants were excluded from the analysis
Unclear– if not clearly reported
 
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes – if study reports ≤ 1 month between index tests
No – if study reports > 1 month between index tests
Unclear – if study does not report the interval between
index tests
 
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
If answers to questions 1), 2), and 3) 'Yes':1.
If answers to any 1 of questions 1), 2), or 3) 'No':2.
If answers to any 1 of questions 1), 2), or 3) 'Unclear':3.
For within-person comparative studies
If answers to all questions 1), 2), 3), and 4) 'Yes':1.
If answers to any 1 of questions 1), 2), 3), or 4) 'No':2.
If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':3.
For non-comparative and between-person comparison
studies
Risk is low1.
Risk is high2.
Risk is unclear3.
For within-person comparative studies
Risk is low1.
Risk is high2.
Risk is unclear3.
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma.
8 Summary study details
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Study
author
Outcomes
reported
Study type Inclusion
criteria
Number
of
patients
/
lesions
US machineFrequency
Resolution
Threshold Observer
qual. (n)
and
experience
 
Reference
standard
Final diagnoses
Exclusions
 
Bessoud
2003
MEL
WPC
P-CS
France
Secondary
Patients with
PSLs
referred
from the
Dermatology
Department
to the
Ultrasound
Unit
111 /
130
 
AU 4 or AU
5 Idea
(Esaote-
Biomedica,
Genoa,
Italy)
Doppler
 
20-MHz
axial 80
µm; lateral
100 µm
7 MHz
 
1. Hypoechoic,
homogenous and
well defined
HFUS+Doppler
As above AND
intra-lesional
vessels present
Not
described
 
Histology
MM 65; 4 BCC; 1
neurosarcoma
BN 33; SK 5;
Other 6 (3
melanosis, 1
thrombosing
capillaritis, 1
histiocytofibroma,
1 lentigo)
16 ‘unseen’ on
ultrasound
(16/130=12%);
5 melanoma;
11 benign nevi
(including 1
lentigo)
Further 8
lesions not
imaged with
Doppler (basis
for selection
NR)
 
Clement
2001
BCC
WPC
P-CS
France
Secondary
Patients with
PSLs
including
melanocytic
and non
melanocytic
examined
before
resection
(recruited
1998-1999)
160 /
176
 
AU4 then
AU5 Idea,
(Esaote
Biomedica,
Genoa,
ltaly)
Doppler
 
20 MHz
80 μm
axial; 100
μm lateral
7 MHz
 
1. Hypoechoic
2. Hypoechoic and
homogenous
3. Hypoechoic and
well defined
HFUS+Doppler
Hypoechoic AND
vascularity
present
Not
described
 
Histology
MM 1; BCC 23;
Mel metastases
6;
BN 6; SK 29;
histiocytofibroma
11; angioma 7
38 not
visualised,
including two
that were
difficult to
reach (38/176
= 21.6%);
5 melanoma
(all in the
horizontal
growth phase;
33 benign
nevus)
 
Dummer
1995
MEL
BCC
NC
NR-CS
Germany
Secondary
Patients with
PSLs
referred
from the
outpatient
clinic to the
Department
of
Dermatology
NR /
792
 
DUB 20 ,
Taberna pro
Medicum,
Luneburg,
Germany
 
20 MHz
axial 80
μm; lateral
200 μm
1. Hypoechoic
2. Hypoechoic and
homogenous
3. Hypoechoic and
well defined (1)
Sharp basal
margins; 2) Sharp
lateral margins)
Not
described
 
Histology
MM 108; BCC 65
BN 307; SK 211;
DF 54; angioma
47
None reported
Harland
2000
NC
CCS
UK
Specialist
Patients with
PSLs with
specific
presumptive
clinical
diagnoses
(SK, BN,
MM) from a
PSL clinic;
the referring
GP had
considered
the
diagnosis of
melanoma
for each
lesion.
NR / 54 Dermascan-
CTM B-
scanner
(Cortex
Technology,
ApS,
Hadsund,
Denmark)
 
20 MHz
axial 50
μm; lateral
300 μm
1. Dermal
echogenicity ratio
(DER) <3 (to
ensure sensitivity
of 100%)
2. Absence of
Entry Echo line
(EEL) - (either
equivalent to
perilesional skin
(nonenhanced) or
as broadened);
3. Either 1. Or 2.
Not
described
 
Histology
MM 19; MiS 6
BN 15; SK 29
BN excluded
from
sensitivity and
specificity
estimates
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Study
author
Outcomes
reported
Study type Inclusion
criteria
Number
of
patients
/
lesions
US machineFrequency
Resolution
Threshold Observer
qual. (n)
and
experience
 
Reference
standard
Final diagnoses
Exclusions
 
Lassau
1997
MEL
BCC
WPC
P-CS
France
Secondary
Patients with
skin lesions
clinically
suspected of
being either
melanoma
or BCC and
scheduled
for resection
70 / 70  
Esaote-
Biomedica
AU4 Idea
(Genoa,
Italy)
Doppler
 
20 MHz
axial 20
µm; lateral
100 µm
7 MHz
 
1. Hypoechoic,
homogenous and
well defined
HFUS+Doppler
As above OR
intratumoral
vessels present
Not
described
 
Histology
MM 19; BCC 31;
neurosarcoma 1
BN 12
 
6/38 clinically
suspected
MEL not
visualised on
HFUS
(including 3
melanomas);
plus 1/32
suspected
BCCs (which
proved to be
an actinic
keratosis);
(7/70 = 10%);
Rallan
2007
NC
CCS
UK
Specialist
Patients
referred to a
skin cancer
clinic with a
suspicion of
melanoma
and with a
subsequent
clinical
diagnosis of
SK, BN, or
suspicion of
melanoma
87 / 87 Dermascan
Cv3 Cortex
ApS,
Denmark);
20 MHz,
modified for
RTI
using a
transducer
with an f-
number of
0.95
  1. presence of
either RTI
contrast, LBI
relative
heterogeneity, OR
EEI relative
heterogeneity;
mechanism/values
indicative of
presence of each
feature NR
Not
described
 
Histology
MM 14; MiS 11
BN 38; SK 24
None reported
NC – non comparative study; WPC – within person comparison study; P – prospective; NR – not reported; CS – case series; CCS
– case control study; HFUS – high frequency ultrasound; PSL – pigmented skin lesion; MEL – melanoma (invasive and in situ);
MM – invasive melanoma; MiS – melanoma in situ; BCC – basal cell carcinoma; BN – benign naevi; SK – seborrhoeic keratosis;
DF – dermatofibroma; RTI – reflex transmission imaging; LBI - lesional backscatter image; EEL - entry echo line; EEI - entry echo
image; DER - dermal echogenicity ratio; GP - general practitioner.
*Also reports in person diagnosis for VI and for Dermoscopy
Graphs
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